0001185185-16-005771.txt : 20161114 0001185185-16-005771.hdr.sgml : 20161111 20161114172646 ACCESSION NUMBER: 0001185185-16-005771 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioSig Technologies, Inc. CENTRAL INDEX KEY: 0001530766 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 264333375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55473 FILM NUMBER: 161996062 BUSINESS ADDRESS: STREET 1: 8441 WAYZATA BLVD STREET 2: SUITE 240 CITY: MINNEAPOLIS STATE: MN ZIP: 55426 BUSINESS PHONE: 763-999-7330 MAIL ADDRESS: STREET 1: 8441 WAYZATA BLVD STREET 2: SUITE 240 CITY: MINNEAPOLIS STATE: MN ZIP: 55426 10-Q 1 biosigtech10q093016.htm 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 10-Q
 
 
(Mark One)
 
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2016
 
or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 000-55473

BIOSIG TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
 
26-4333375
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

8441 Wayzata Blvd, Suite 240
Minneapolis, MN 55426
(Address of principal executive offices) (zip code)

(763) 999-7331
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
 Large accelerated filer                                                                   ☐
 Accelerated filer                                                                            ☐
 Non-accelerated filer                                                                     ☐
 Smaller reporting company                                                          ☒
(Do not check if a smaller reporting company)
 
          
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐   No ☒

As of November 14, 2016, there were 20,950,093 shares of registrant’s common stock outstanding.  

TABLE OF CONTENTS
 
PART I.
FINANCIAL INFORMATION
 
 
 
 
 
 
 
 
ITEM 1.
 
 
 
 
 
 
 
 
 
 
3
 
 
 
 
 
 
 
 
4
 
 
 
 
 
 
 
 
5
 
 
 
 
 
 
 
 
6
 
 
 
 
 
 
 
 
7-23
 
 
 
 
 
 
ITEM 2.
 
24-33
 
ITEM 3.
 
33
 
ITEM 4.
 
33
 
 
 
 
 
PART II.
OTHER INFORMATION
 
 
 
 
 
 
 
 
ITEM 1.
 
33
 
ITEM 1A.
 
33
 
ITEM 2.
 
34
 
ITEM 3.
 
34
 
ITEM 4.
 
34
 
ITEM 5.
 
34
 
ITEM 6.
 
35
 
 
 
 
 
 
 
36

 
PART 1 – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS
 
BIOSIG TECHNOLOGIES, INC.
  
CONDENSED BALANCE SHEETS
  
   
 
  
September 30,
    
December 31,
  
 
  
2016
    
2015
  
 
  
(unaudited)
        
 
            
ASSETS
            
Current assets:
            
Cash
  
$
150,454
    
$
953,234
  
Prepaid expenses
    
134,530
      
31,308
  
  Total current assets
    
284,984
      
984,542
  
 
                
Property and equipment, net
    
22,692
      
18,408
  
 
                
Other assets:
                
Deposits
    
27,612
      
27,612
  
 
                
  Total assets
  
$
335,288
    
$
1,030,562
  
 
                
LIABILITIES AND STOCKHOLDERS’ DEFICIT
                
Current liabilities:
                
Accounts payable and accrued expenses, including $8,703 and $12,716 to related parties as of September 30, 2016 and December 31, 2015, respectively
  
$
426,497
    
$
223,546
  
Dividends payable
    
341,403
      
340,291
  
Warrant liability
    
2,324,460
      
1,621,199
  
Derivative liability
    
291,086
      
285,157
  
  Total current  liabilities
    
3,383,446
      
2,470,193
  
 
                
Series C Preferred Stock, 1,090 and 1,471 shares issued and outstanding; liquidation preference of $1,090,000 and $1,471,000 as of September 30, 2016 and December 31, 2015, respectively
    
1,090,000
      
1,471,000
  
 
                
Stockholders’ deficit
                
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock
                
Common stock, $0.001 par value, authorized 50,000,000 shares, 20,935,093 and 16,825,703 issued and outstanding as of September 30, 2016 and December 31, 2015, respectively
    
20,935
      
16,826
  
Additional paid in capital
    
38,295,183
      
29,314,399
  
Accumulated deficit
    
(42,454,276
)
    
(32,241,856
)
  Total stockholders’ deficit
    
(4,138,158
)
    
(2,910,631
)
 
                
Total liabilities and stockholders’ deficit
  
$
335,288
    
$
1,030,562
  
 
 
See the accompanying notes to the unaudited condensed financial statements

BIOSIG TECHNOLOGIES, INC.
  
CONDENSED STATEMENTS OF OPERATIONS
  
(unaudited)
  
 
                        
 
  
Three months ended September 30,
    
Nine months ended September 30,
  
 
  
2016
    
2015
    
2016
    
2015
  
Operating expenses:
                        
Research and development
  
$
560,514
    
$
354,471
    
$
2,139,671
    
$
1,146,113
  
General and administrative
    
991,852
      
2,117,010
      
7,257,852
      
8,801,878
  
Depreciation
    
2,570
      
2,607
      
7,811
      
7,948
  
  Total operating expenses
    
1,554,936
      
2,474,088
      
9,405,334
      
9,955,939
  
 
                                
Loss from operations
    
(1,554,936
)
    
(2,474,088
)
    
(9,405,334
)
    
(9,955,939
)
 
                                
Other income (expense):
                                
Gain (loss) on change in fair value of derivatives
    
17,771
      
2,851,755
      
(807,087
)
    
3,050,318
  
Interest income (expense)
    
-
      
-
      
1
      
(1,298
)
Financing costs
    
-
      
-
      
-
      
(529,704
)
 
                                
  Total other income (expense)
    
17,771
      
2,851,755
      
(807,086
)
    
2,519,316
  
 
                                
(Loss) income before income taxes
    
(1,537,165
)
    
377,667
      
(10,212,420
)
    
(7,436,623
)
 
                                
Income taxes (benefit)
    
-
      
-
      
-
      
-
  
 
                                
Net (loss) income
    
(1,537,165
)
    
377,667
      
(10,212,420
)
    
(7,436,623
)
 
                                
Preferred stock dividend
    
(24,726
)
    
(53,048
)
    
(85,467
)
    
(244,516
)
 
                                
NET (LOSS) INCOME AVAILABLE TO COMMON STOCKHOLDERS
  
$
(1,561,891
)
  
$
324,619
    
$
(10,297,887
)
  
$
(7,681,139
)
 
                                
Net (loss) income per common share, basic and diluted
  
$
(0.08
)
  
$
0.02
    
$
(0.55
)
  
$
(0.57
)
 
                                
Weighted average number of common shares outstanding, basic and diluted
    
20,581,041
      
14,849,127
      
18,847,515
      
13,565,453
  

 
See the accompanying notes to the unaudited condensed financial statements

 
BIOSIG TECHNOLOGIES, INC.
  
CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT
  
NINE MONTHS ENDED SEPTEMBER 30, 2016
  
 
                      
               
Additional 
              
   
Common stock
    
Paid in 
    
Accumulated
        
   
Shares
    
Amount
    
Capital
    
Deficit
    
Total
  
Balance, January 1, 2016
    
16,825,703
    
$
16,826
    
$
29,314,399
    
$
(32,241,856
)
  
$
(2,910,631
)
Sale of common stock
    
2,208,514
      
2,208
      
3,051,660
      
-
      
3,053,868
  
Common stock issued for services
    
1,335,000
      
1,335
      
2,469,715
      
-
      
2,471,050
  
Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share
    
254,000
      
254
      
380,746
      
-
      
381,000
  
Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.58 per share
    
53,331
      
53
      
84,302
      
-
      
84,355
  
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares
    
-
      
-
      
97,897
      
-
      
97,897
  
Stock based compensation
    
258,545
      
259
      
2,981,931
      
-
      
2,982,190
  
Preferred Stock dividend
    
-
      
-
      
(85,467
)
    
-
      
(85,467
)
Net loss
    
-
      
-
      
-
      
(10,212,420
)
    
(10,212,420
)
  Balance, September 30, 2016 (unaudited)
    
20,935,093
    
$
20,935
    
$
38,295,183
    
$
(42,454,276
)
  
$
(4,138,158
)
 
See the accompanying notes to the unaudited condensed financial statements



BIOSIG TECHNOLOGIES, INC.
  
CONDENSED STATEMENTS OF CASH FLOWS
  
(unaudited)
  
             
   
Nine months ended September 30,
  
   
2016
    
2015
  
CASH FLOWS FROM OPERATING ACTIVITIES:
            
Net loss
  
$
(10,212,420
)
  
$
(7,436,623
)
Adjustments to reconcile net loss to cash used in operating activities:
                
Depreciation
    
7,811
      
7,948
  
Amortization of debt discount
    
-
      
585,324
  
Change in derivative liabilities
    
807,087
      
(3,050,318
)
Equity based compensation
    
5,453,240
      
6,907,423
  
Changes in operating assets and liabilities:
                
Prepaid expenses
    
(103,222
)
    
(8,141
)
Accounts payable
    
202,534
      
(213,754
)
Stock based payable
    
-
      
(226,305
)
Deferred rent payable
    
417
      
2,713
  
  Net cash used in operating activities
    
(3,844,553
)
    
(3,431,733
)
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
                
Purchase of property and equipment
    
(12,095
)
    
(8,971
)
Payment of long term deposit
    
-
      
(2,612
)
  Net cash used in investing activity
    
(12,095
)
    
(11,583
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
                
Proceeds from sale of common stock
    
3,053,868
      
3,042,213
  
Proceeds from sale of Series C preferred stock
    
-
      
450,000
  
Proceeds from exercise of options
    
-
      
20,900
  
Proceeds from exercise of warrants
    
-
      
24,981
  
  Net cash provided by financing activities
    
3,053,868
      
3,538,094
  
                 
Net (decrease) increase in cash and cash equivalents
    
(802,780
)
    
94,778
  
                 
Cash and cash equivalents, beginning of the period
    
953,234
      
239,781
  
Cash and cash equivalents, end of the period
  
$
150,454
    
$
334,559
  
                 
Supplemental disclosures of cash flow information:
                
Cash paid during the period for interest
  
$
-
    
$
1,298
  
Cash paid during the period for income taxes
  
$
-
    
$
-
  
                 
Non-cash investing and financing activities:
                
Common stock issued upon conversion of Series C Preferred Stock and accrued dividends
  
$
465,355
    
$
1,654,811
  
See the accompanying notes to the unaudited condensed financial statements


BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
 
The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
 
The condensed balance sheet as of December 31, 2015 has been derived from audited financial statements.
 
Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 14, 2016.
 
NOTE 2 –GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS
 
As of September 30, 2016, the Company had cash of $150,454 and working capital deficit (current liabilities in excess of current assets) of $3,098,462 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised approximately $450,000 in October 2016 through the sale of common stock and warrants (See Note 11). As of September 30, 2016, excluding the derivative and warrant liabilities, the Company's working capital deficit would have been $482,916. During the nine months ended September 30, 2016, the Company used net cash in operating activities of $3,844,553.  These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 2 months.

The Company's primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders' deficiencies at September 30, 2016 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
 
Accordingly, the accompanying condensed financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.


BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Fair Value of Financial Instruments
Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
 
The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
 
Derivative Instrument Liability
The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.

At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).

Research and development costs
The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514 and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

Net Earnings (Loss) Per Common Share
The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
 
The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.

Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:
 
 
  
September 30,
2016
    
September 30,
2015
  
Series C convertible preferred stock
    
726,667
      
1,238,667
  
Options to purchase common stock
    
8,090,190
      
7,405,190
  
Warrants to purchase common stock
    
8,333,235
      
6,372,677
  
Totals
    
17,150,092
      
16,474,467
  
 
Stock Based Compensation
The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested.

As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested.

Income Taxes
The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate.  Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.

Registration Rights
The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.
 
Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on April 29, 2016. On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.

Reclassification
Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.

Recent Accounting Pronouncements
There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent Events
The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

NOTE 4 – PROPERTY AND EQUIPMENT
 
Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows:
 
 
  
September 30,
2016
    
December 31,
2015
  
Computer equipment
  
$
80,544
    
$
68,449
  
Furniture and fixtures
    
10,117
      
10,117
  
Subtotal
    
90,661
      
78,566
  
Less accumulated depreciation
    
(67,969
)
    
(60,158
)
Property and equipment, net
  
$
22,692
    
$
18,408
  
 
Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
 
Depreciation expense was $2,570 and $7,811 for the three and nine months ended September 30, 2016, respectively; and $2,607 and $7,948 for the three and nine months ended September 30, 2015, respectively.

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 
Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following:
 
 
  
September 30,
2016
    
December 31,
2015
  
Accrued accounting and legal
  
$
185,630
    
$
112,723
  
Accrued reimbursements
    
-
      
13,613
  
Accrued consulting
    
3,500
      
15,200
  
Accrued research and development expenses
    
177,577
      
34,179
  
Accrued office and other
    
7,190
      
31,482
  
Accrued payroll
    
35,835
      
-
  
Deferred rent
    
3,432
      
3,016
  
Accrued settlement related to arbitration
    
13,333
      
13,333
  
 
  
$
426,497
    
$
223,546
  

NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK
 
On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:
 
●
incur additional indebtedness;
●
permit liens on assets;
●
repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;
●
pay cash dividends to our stockholders; and
●
engage in transactions with affiliates.
 
Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.

In the event that:
  (i)  
we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,
(ii)  
we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,
(iii)  
we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,
 (iv)  
we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,
(v)  
we are party to a change of control transaction,
(vi)  
we file for bankruptcy or a similar arrangement or are adjudicated insolvent,
(vii)  
we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,


BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity.
 
In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. 

As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.

In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense.
 
During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock.

During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910.

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There was no established market for the Company’s common stock.  As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.
 
At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%.
 
In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.
 
In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

For the nine months ended September 30, 2016, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $97,897 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.23% to 0.59%, a dividend yield of 0%, and volatility of 141% to 150%.
 
Series C Preferred Stock issued and outstanding totaled 1,090 and 1,471 as of September30, 2016 and December 31, 2015, respectively.  As of September 30, 2016 and December 31, 2015, the Company has accrued $341,403 and $340,291 dividends payable on the Series C Preferred Stock.

Registration Rights Agreement
In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.
 
Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.
 
The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.  As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement as of December 31, 2014. At December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.

NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.

The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%.

At September 30, 2016, the Company marked to market the fair value of the reset provisions of the Series C Preferred Stock and warrants and determined fair values of $291,086 and $2,324,460, respectively. The Company recorded a gain(loss) from change in fair value of derivatives of $17,771 and $(807,087) for the three and nine months ended September 30, 2016. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 0.49 to 3.61 years, a risk free interest rate of 0.39% to 1.01%, a dividend yield of 0%, and volatility of 143.00% to 152.00%.

NOTE 8 – STOCKHOLDER EQUITY

Preferred stock
The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of September 30, 2016 and December 31, 2015, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 shares of Series C Preferred Stock. As of September 30, 2016 and December 31, 2015, there were no outstanding shares of Series A and Series B preferred stock.

In February 2016, the Company issued 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.
 

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

As of September 30, 2016 and December 31, 2015, the Company has 1,090 and 1,471 Series C Preferred Stock issued and outstanding.

Common stock
The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of September 30, 2016 and December 31, 2015, the Company had 20,935,093 and 16,825,703 shares issued and outstanding, respectively.

During the nine months ended September 30, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share).

During the nine months ended September 30, 2016, the Company issued an aggregate of 545,000 shares of common stock  for services rendered totaling $1,051,850 ($1.93 average per share).

During the nine months ended September 30, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,208,514 shares of common stock and 1,254,550 warrants for aggregate proceeds of $3,053,868, net of $278,188 in expenses.

During the nine months ended September 30, 2016, the Company issued 175,000 shares of common stock as vested previously issued restricted stock units

During the nine months ended September 30, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement. 

The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter.  The final closing under the Private Placement occurred on April 29, 2016.  On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

Options
On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 11,686,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.
 
Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan.

During the nine months ended September 30, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers, directors and key consultants.

During the nine months ended September 30, 2016, the Company granted an aggregate of 873,545 stock grants to officers, employees and key consultants under the plan. See Note 8.

The following table presents information related to stock options at September 30, 2016:

Options Outstanding
  
Options Exercisable
  
       
Weighted
      
       
Average
  
Exercisable
  
Exercise
  
Number of
  
Remaining Life
  
Number of
  
Price
  
Options
  
In Years
  
Options
  
 
$
1.01-2.00
      
2,139,642
      
6.8
      
1,572,642
  
   
2.01-3.00
      
5,650,548
      
5.6
      
4,872,457
  
   
3.01-4.00
      
300,000
      
8.5
      
300,000
  
           
8,090,190
      
6.0
      
6,745,099
  

A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2016 is as follows:
BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

 
              
Weighted-Average
        
 
        
Weighted-Average
    
Remaining
    
Aggregate
  
 
  
Shares
    
Exercise Price
    
Contractual Term
    
Intrinsic Value
  
Outstanding at January 1, 2016
    
7,780,190
    
$
2.30
      
6.4
    
$
-
  
Grants
    
750,000
      
1.80
      
10.0
      
-
  
Exercised
    
-
                          
Forfeiture/Canceled
    
(440,000
)
  
$
2.24
      
-
      
-
  
Outstanding at September 30, 2016
    
8,090,190
    
$
2.26
      
6.0
    
$
12,350
  
Exercisable at September 30, 2016
    
6,745,099
    
$
2.31
      
6.0
    
$
3,563
  

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.52 as of September 30, 2016, which would have been received by the option holders had those option holders exercised their options as of that date.
 
Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from using the Company’s historical stock prices for 2016. Prior to 2016, the Company derived the volatility figure from an index of historical stock prices for comparable entities. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification.

The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. 

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.
 
The Company estimated forfeitures related to option grants at a weighted average annual rate of  0% per year, as the Company does not yet have adequate historical data, for options granted during the nine months ended September 30, 2016 and 2015.

The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015:

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

 
September 30,
2016
 
September 30,
2015
 
Risk-free interest rate
 
 
1.08% - 1.69
%
 
 
1.19% - 2.37
%
Dividend yield
 
 
0
%
 
 
0
%
Stock price volatility
 
 
122.82
%
 
 
118.56% -130.30
%
Expected life
5 – 10 years
 
7-10 years
 
Weighted average grant date fair value
 
$
1.50
 
 
$
2.41
 

During the nine months ended September 30, 2016, the Company granted an aggregate of  685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent.

The fair value of all options vesting during the three and nine months ended September 30, 2016 of $218,085 and $2,512,886, respectively, and during the three and nine months ended September 30, 2015 of $836,425 and $3,793,152, respectively, was charged to current period operations.  Unrecognized compensation expense of $406,988 at September 30, 2016 will be expensed in future periods.

Restricted Stock
The following table summarizes the restricted stock activity for the nine months ended September 30, 2016:
 
Restricted shares issued as of January 1, 2016
    
175,000
  
Granted
    
180,000
  
Vested
    
(175,000
)
Total restricted shares issued as of September 30, 2016
    
180,000
  
Vested restricted shares as of September 30, 2016
    
-
  
Unvested restricted shares as of September 30, 2016
    
180,000
  
 
On September 7, 2016, the Company granted 180,000 restricted stock units (“RSU”) to a consultant vesting monthly over one year beginning October 7, 2016.
 
Stock based compensation expense related to restricted stock grants was $70,753 and $124,139 for the three months ended September 30, 2016, respectively; and $100,492 and $238,122 for the three and nine months ended September 30, 2015,  respectively. As of September 30, 2016, the stock-based compensation relating to restricted stock of $202,847 remain unamortized and is expected to be amortized over the remaining period of approximately 1 year.    


BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)
 
Warrants
The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016: 

Exercise
    
Number
  
Expiration
Price
    
Outstanding
  
Date
$
0.001
      
383,320
  
January 2020
$
1.50
      
4,173,017
  
February 2018 to May 2020
$
1.84
      
35,076
  
January 2020
$
1.95
      
1,689,026
  
October 2018 to September 2019
$
2.00
      
100,000
  
August 2018
$
2.02
      
30,755
  
January 2020
$
2.10
      
38,572
  
June 2019
$
2.50
      
100,000
  
August 2018
$
2.75
      
228,720
  
August 2019 to September 2019
$
3.67
      
214,193
  
December 2018 to January 2019
$
3.75
      
1,340,556
  
April 2019 to March 2020
         
8,333,235
  
 

On February 9, 2016, the Company issued 25,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services.

On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services.

On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 18,040 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services.

On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 17,996 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services.

On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company’s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services.

On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company’s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company’s common stock.

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company’s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company’s common stock.

On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company’s common stock.

Stock based compensation related to warrants issued for services was $641 and $56,930 for the three and nine months ended September 30, 2016, respectively; and $44,464 for the three and nine months ended September 30, 2015.
 
A summary of the warrant activity for the nine months ended September 30, 2016 is as follows:

 
              
Weighted-Average
        
 
        
Weighted-Average
    
Remaining
    
Aggregate
  
 
  
Shares
    
Exercise Price
    
Contractual Term
    
Intrinsic Value
  
Outstanding at January 1, 2016
    
7,078,685
    
$
2.02
      
3.0
      
497,933
  
Grants
    
1,254,550
      
1.90
      
2.5
      
-
  
Exercised
    
-
                          
Canceled
    
-
                          
Outstanding at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
 
                                
Vested and expected to vest at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
Exercisable at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.52 as of September 30, 2016, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

NOTE 10 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:


BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
 
All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of September 30, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company.

As of September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.

The derivative and warrant liability as of September 30, 2016, in the amount of $291,086 and $2,324,460, respectively, has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2016:

BIOSIG TECHNOLOGIES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

 
  
Warrant
Liability
    
Derivative
  
Balance, December 31, 2015
  
$
1,621,199
    
$
285,157
  
Total (gains) losses
                
Transfers out due to conversion of Series C Preferred Stock
    
-
      
(97,897
)
Mark to market to September 30, 2016
    
703,261
      
103,826
  
Balance, September 30, 2016
  
$
2,324,460
    
$
291,086
  
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016
  
$
(703,261
)
  
$
(103,826
)

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.
 
NOTE 11 – SUBSEQUENT EVENTS
 
On October 16, 2016, the Company issued 15,000 shares of its common stock to a consultant for services rendered valued at $22,800.
 
On October 28, 2016, the Company entered into securities purchase agreements with investors, pursuant to which the Company received from subscriptions for the purchase of 346,567 shares of the Company’s common stock and warrants to purchase 173,284 shares of our common stock at $1.50, expiring three years from issuance, for aggregate net cash proceeds of $450,477, after financing costs of $69,373.

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management’s current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue,” or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
 
Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Factors that could cause differences include, but are not limited to, expected market demand for our products, fluctuations in pricing for materials, and competition.
 
Business Overview
We are a development stage medical device company that is developing a proprietary technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.  We are developing the PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures.
 
The PURE EP System is designed to assist electrophysiologists in making clinical decisions in real-time by providing information that, we believe, is not always easily obtained, if at all, from any other equipment presently used in electrophysiology labs.  The PURE EP System’s ability to acquire high fidelity cardiac signals will potentially increase these signals’ diagnostic value, and therefore offer improved accuracy and efficiency of the EP studies and related procedures.  We are developing signal processing tools within the PURE EP System. We believe that these will assist electrophysiologists in further differentiating true signals from noise, and will provide guidance in identifying ablation targets.

Since June 2011, we have collaborated with physicians affiliated with the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas for initial technology validation.  The physicians affiliated with the Texas Cardiac Arrhythmia Institute have provided us with digital recordings obtained with conventional electrophysiology recording systems during different stages of electrophysiology studies.  Using our proprietary signal processing tools that are part of the PURE EP System, we analyzed these recordings and successfully removed baseline wander, noise and artifacts from the data thereby providing better diagnostic quality signals.
 
We are focused on improving the quality of cardiac recordings obtained during ablation of atrial fibrillation, the most common cardiac arrhythmia, and ventricular tachycardia, an arrhythmia evidenced by a fast heart rhythm originating from the lower chambers of the heart, which can be life-threatening. Cardiac ablation is a procedure that corrects conduction of electrical impulses in the heart that cause arrhythmias.  During this invasive procedure, a catheter is usually inserted using a venous access into a specific area of the heart. A special radiofrequency generator delivers energy through the catheter to small areas of the heart muscle that cause the abnormal heart rhythm.  
According to a 2009 article in Circulation: Arrhythmia and Electrophysiology, ablation is superior to pharmacological treatments and is becoming a first line of therapy for certain patients with arrhythmias (“Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation,” Circulation: Arrhythmia and Electrophysiology (2009) 2: 349-361).

Our overall goal is to establish our proprietary technology as a new platform that will have the following advantages over the electrophysiology recording systems currently available on the market:
 
·
Higher quality cardiac signal acquisition for accurate and more efficient electrophysiology studies;

·
Precise, uninterrupted, real time evaluations of electrograms;

·
Reliable cardiac recordings to better determine precise ablation targets, strategy and end point of procedures; and

·
A portable device that can be fully integrated into existing electrophysiology lab environments.
 
If we are able to develop our product as designed, we believe that the PURE EP System and its signal processing tools will contribute to an increase in the number of procedures performed in each electrophysiology lab and possibly improved patient outcomes.
 
Our significant scientific achievements to date include:

·
Initial system concept validation has been performed in collaboration with physicians at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas in June 2011.  The Texas Cardiac Arrhythmia Institute provided challenging recordings obtained with electrophysiology recording systems presently in use at the institute during various electrophysiology studies. Our technology team successfully imported the data into the PURE EP System software and using proprietary signal processing, the PURE EP System software was able to reduce baseline wander, noise, and artifacts from the data and therefore provide better diagnostic quality signals.

·
We have established clinical and/or advisory relationships for both technology development and validation studies with physicians and researchers affiliated with the following medical centers: Texas Cardiac Arrhythmia Institute, Austin, TX; Cardiac Arrhythmia Center at the University of California at Los Angeles, Los Angeles, CA; Mount Sinai Medical Center, New York, NY; Beaumont Medical Center, Detroit, MI; University Hospitals Case Medical Center, Cleveland, OH; The Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and Mayo Clinic, Rochester, MN.
 
·
The Cardiac Arrhythmia Center at the University of California at Los Angeles and Dr. Kalyanam Shivkumar, a former member of our board of directors, have played a significant role in the initial functional testing of our hardware.  Dr. Shivkumar and his team have enabled us to learn the connectivity of the lab and its devices that pertain to where our PURE EP System will fit in. In June 2013, we commenced our first proof of concept pre-clinical study with the assistance of Dr. Shivkumar in order to further test the components of the PURE EP System hardware, as further explained below.


·
We are developing signal processing tools within the PURE EP System that will assist electrophysiologists in further differentiating true signals from noise, which may potentially provide guidance in identifying ablation targets.  The signal processing tools are expected to be an integral part of the software of the PURE EP System, which we believe will significantly facilitate the locating of ablation targets.

·
In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac simulator at our lab, and subsequently by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles.  As part of the testing, we simultaneously recorded electrocardiogram and intracardiac signals on our proof of concept unit and GE’s CardioLab recording system. An identical signal was applied to the input of both systems and the monitor of our proof of concept unit was positioned next to the monitor of GE’s CardioLab recording system to allow for visual comparison. We believe that our proof of concept unit performed well as compared to GE’s CardioLab recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals displayed on GE’s CardioLab recording system.  However, because this was a proof of concept test, without any clearly established protocols, we cannot present this data for publication and we do not have any independent verification or peer review of these findings.

·
In the third quarter of 2013, we analyzed the results of our proof of concept unit to determine the final design of the PURE EP System prototype, which has since been completed.  

·
In September 2014, we performed additional tests on the PURE EP System prototype at the University of California at Los Angeles.  

·
In the fourth quarter of 2014, we appointed Dr. Samuel J. Asirvatham from the Mayo Clinic as a member of our Scientific Advisory Board and initiated plans for pre-clinical studies at the Mayo Clinic.

·
In the first quarter of 2015, we appointed Dr. K. L. Venkatachalam from the Mayo Clinic as a member of our Scientific Advisory Board.  On March 31, 2015 Drs. Asirvatham and Venkatachalam performed our first pre-clinical study at the Mayo Clinic in Rochester, MN.

·
On June 10, 2015, Dr. Asirvatham performed our second pre-clinical study at the Mayo Clinic in Rochester, Minnesota.

·
On November 17, 2015, Dr. Asirvatham performed our third pre-clinical study at the Mayo Clinic in Rochester, Minnesota.

·
On February 22, 2016, we signed an agreement to initiate development of its PURE EP System with Minnetronix and are taking steps toward its 510(k) submission.

·
On March 28, 2016, we announced an Advanced Research Program with Dr. Asirvatham at the Mayo Clinic beginning June 2016.

·
On June 2, 2016, Dr. Asirvatham performed our fourth pre-clinical study at the Mayo Clinic in Rochester, Minnesota which launched the Advanced Research Program.

·
On June 23, 2016, Dr. Vivek Reddy performed an initial pre-clinical study at The Mount Sinai Hospital in New York, New York.

 
We conducted our first, second, and third pre-clinical studies on March 31, 2015, June 10, 2015 and November 17, 2015 respectively, and conducted our fourth pre-clinical study on June 2, 2016, which began an advanced research program at the Mayo Clinic in Rochester, Minnesota with the PURE EP System prototype. Additionally, we conducted an initial pre-clinical study at The Mount Sinai Hospital in New York, New York on June 23, 2016. We also intend to conduct a pre-clinical study at the Cardiac Arrhythmia Center at the University of California at Los Angeles with emphasis on the ventricular tachycardia (VT) model. We intend to conduct further pre-clinical studies, end-user preference studies, and research studies. The main objective of these studies is to demonstrate the clinical potential of the PURE EP System. We have initiated technology development with Minnetronix, a medical technology and innovation company, and are implementing steps for obtaining 510(k) approval from the U.S. Food and Drug Administration for the PURE EP System.
 
We believe that by the first half of 2017, we will have obtained 510(k) marketing clearance from the FDA and will be able to commence marketing and commercialization of the PURE EP System.  Our ability to achieve the aforementioned milestones will be principally determined by our ability to obtain necessary financing and regulatory approvals, among other factors.

Because we are a development stage company, with our initial product under development, we currently do not have any customers.  We anticipate that our initial customers will be hospitals and other health care facilities that operate electrophysiology labs.

Results of Operations
 
We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development efforts and the timing and outcome of regulatory submissions. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.

Three Months Ended September 30, 2016 Compared to Three Months Ended September 30, 2015
 
Revenues and Cost of Goods Sold. We had no revenues or cost of goods sold during the three months ended September 30, 2016 and 2015.
 
Research and Development Expenses. Research and development expenses for the three months ended September 30, 2016 were $560,514, an increase of $206,043, or 58.1%, from $354,471 for the three months ended September 30, 2015. We increased our activity level, personnel and consulting expenses as compared to three months ended September 30, 2015.

General and Administrative Expenses. General and administrative expenses for the three months ended September 30, 2016 were $991,852, a decrease of $1,125,158, or 53.1%, from $2,117,010 incurred in the three months ended September 30, 2015. This decrease is primarily due to a decrease in stock based compensation issued to employees and consultants in the current period as compared to the same period in the prior year and less service provider fees paid.
 
Payroll related expenses increased to $292,275 in the current period from $178,212 for the three months ended September 30, 2015, an increase of $114,063.  The increase was due to pay increases and added personnel in the current period.   We incurred $223,986 in stock based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the three months ended September 30, 2016 as compared to $1,416,737 in stock based compensation for the same period in 2015.


Professional services for the three months ended September 30, 2016 totaled $49,176, a decrease of $3,125, or 6.0%, over the $52,301 recognized for the three months ended September 30, 2015. Of professional services, legal fees totaled $36,173 for the three months ended September 30, 2016, a decrease of $10,128, or 21.9%, from $46,301 incurred for the three months ended September 30, 2015.  Accounting fees incurred in the three months ended September 30, 2016 amounted to $13,000, an increase of $7,000, or 116.7%, from $6,000 incurred in same period last year.  The increase in accounting fees were primarily due to registration statement filings in the current period. 

Consulting, public and investor relations fees for the three months ended September 30, 2016 were $226,065 as compared to $316,148 incurred for the three months ended September 30, 2015. The decrease in consulting and investor relations fees during the three months ended September 30, 2016 relate to our continued efforts to develop our recognition throughout the medical industry.
 
Travel, meals and entertainment costs for the three months ended September 30, 2016 were $48,600, a decrease of $24,930, or 33.9%, from $73,530 incurred in the three months ended September 30, 2015. Travel, meals and entertainment costs include travel related to business development and financing. Rent for the three months ended September 30, 2016 totaled $32,478, a decrease of $50,075 or 60.7%, from $82,553 incurred in three months ended September 30, 2015.  During the three months ended September 30, 2015, we incurred additional rent due to providing temporary housing for summer interns as compared to $-0- for the current period.

Depreciation Expense. Depreciation expense for the three months ended September 30, 2016 totaled $2,570 a decrease of $37, or 1.4%, over the expense of $2,607 incurred in the three months ended September 30, 2015, as a result of the aging of office computers and other equipment.

Gain on change in fair values of derivatives.  Beginning in March 2015, we are required to estimate the fair value of the embedded beneficial conversion features of our issued Series C Preferred Stock and certain warrants with reset (anti-dilution) provisions.  During the three months ended September 30, 2016, we incurred a gain on change in fair values of these derivatives of $17,771 as compared to a gain of $2,851,755 for the same period during the prior year.
 
Preferred Stock Dividend. Preferred stock dividend for the three months ended September 30, 2016 totaled $24,726, a decrease of $28,322, or 53.4% from $53,048 incurred during the three months ended September 30, 2015. Preferred stock dividends are primarily related to the issuance of our Series C Preferred Stock from 2013 through 2015.  The reduction in 2016 as compared to 2015 is the result of conversions of the Series C Preferred Stock.  
 
Net( Loss) Income. As a result of the foregoing, net loss for the three months ended September 30, 2016 was $1,561,891 compared to a net income of $324,619 for the three months ended September 30, 2015.

Nine Months Ended September 30, 2016 Compared to Nine Months Ended September 30, 2015
 
Revenues and Cost of Goods Sold. We had no revenues or cost of goods sold during the nine months ended September 30, 2016 and 2015.
 
Research and Development Expenses. Research and development expenses for the nine months ended September 30, 2016 were $2,139,671, an increase of $993,558, or 86.7%, from $1,146,113 for the nine months ended September 30, 2015. This increase is primarily stock based compensation during the nine months ended September 30, 2016 of $735,782 as compared to $214,753 for same period, last year.  In addition, we increased our activity level, personnel and consulting expenses as compared to nine months ended September 30, 2015.

 
General and Administrative Expenses. General and administrative expenses for the nine months ended September 30, 2016 were $7,257,852, a decrease of $1,544,026, or 17.6%, from $8,801,878 incurred in the nine months ended September 30, 2015. This decrease is primarily due to less stock based compensation issued to employees and consultants in the current period as compared to the same period in the prior year.
 
Payroll related expenses increased to $894,995 in the current period from $827,470 for the nine months ended September 30, 2015, an increase of $67,525.  The increase was due to added personnel and increases in pay in the current period.   We incurred $4,717,458 in equity based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the nine months ended September 30, 2016 as compared to $6,692,670 in stock based compensation for the same period in 2015.
 
Professional services for the nine months ended September 30, 2016 totaled $260,990, a decrease of $48,875, or 15.8%, over the $309,865 recognized for the nine months ended September 30, 2015. Of professional services, legal fees totaled $193,490 for the nine months ended September 30, 2016, a decrease of $46,375, or 19.3%, from $239,865 incurred for the nine months ended September 30, 2015.  Accounting fees incurred in the nine months ended September 30, 2016 amounted to $67,500, a decrease of $2,500, or 3.6%, from $70,000 incurred in same period last year.  

Consulting, public and investor relations fees for the nine months ended September 30, 2016 were $971,932 as compared to $628,550 incurred for the nine months ended September 30, 2015. The increase in consulting and investor relations fees during the nine months ended September 30, 2016 relate to our efforts to develop our recognition throughout the medical industry.
 
Travel, meals and entertainment costs for the nine months ended September 30, 2016 were $195,878, a decrease of $42,398, or 17.8%, from $238,276 incurred in the nine months ended September 30, 2015. Travel, meals and entertainment costs include travel related to business development and financing. Rent for the nine months ended September 30, 2016 totaled $96,513, a decrease of $37,399 or 27.9%, from $133,912 incurred in nine months ended September 30, 2015, primarily due to prior year housing of temporary interns, net with expansion to our corporate office in Minnesota.

Depreciation Expense. Depreciation expense for the nine months ended September 30, 2016 totaled $7,811, a decrease of $137, or 1.7%, over the expense of $7,948 incurred in the nine months ended September 30, 2015, as a result of the aging of our office computers and other equipment.

Loss (gain) on change in fair values of derivatives.  Beginning in March 2015, we are required to estimate the fair value of the embedded beneficial conversion features of our issued Series C Preferred Stock and certain warrants with reset (anti-dilution) provisions.  During the nine months ended September 30, 2016, we incurred a loss on change in fair values of these derivatives of $807,087 as compared to a gain of $3,050,318 for the same period during the prior year.

Interest Income (expense).  Interest income (expense) for the nine months ended September 30, 2016 totaled $1, an increase of $1,299 from interest expense of $1,298 incurred during the same period last year. In the nine months ended September 30, 2015, our interest income was primarily related to our bank money market account and interest costs were primarily related to credit card financing charges.

Financing Costs.  Financing costs for the nine months ended September 30, 2015 totaled $529,704 as compared to $-0- the current period. Financing costs were primarily related to the beneficial conversion feature in our Series C Preferred Stock. During 2015, upon issuance of additional Series C Preferred Stock and associated warrants, we incurred additional financing costs related to the conversion features.
 
Preferred Stock Dividend. Preferred stock dividend for the nine months ended September 30, 2016 totaled $85,467, a decrease of $159,049, or 65.0% from $244,516 incurred during the nine months ended September 30, 2015. Preferred stock dividends are primarily related to the issuance of our Series C Preferred Stock from 2013 through 2015.  The reduction in 2016 as compared to 2015 is the result of conversions of the Series C Preferred Stock.  
 
Net Loss. As a result of the foregoing, net loss for the nine months ended September 30, 2016 was $10,297,887 compared to a net income of $7,681,139 for the nine months ended September 30, 2015.

Liquidity and Capital Resources
 
Nine Months Ended September 30, 2016 Compared to Nine Months Ended September 30, 2015
 
As of September 30, 2016, we had a working capital deficit (current liabilities in excess of current assets) of $3,098,462, comprised of cash of $150,454 and prepaid expenses of $134,530, which was offset by $426,497 of accounts payable and accrued expenses, accrued dividends on preferred stock issuances of $341,403 and an aggregate of $2,615,546 of warrant and derivative liabilities. Excluding the warrant and derivative liabilities, the Company’s working capital deficit would have been $482,916.  For the nine months ended September 30, 2016, we used $3,844,553 of cash in operating activities and $12,095 of cash in investing activities. Cash provided by financing activities totaled $3,053,868, comprised of proceeds from the sale of our common stock. In the comparable period in 2015, our aggregate cash provided by financing activities totaled $3,538,094 comprised of $3,042,213 raised through the sale of our common stock, $450,000 from the sale of our Series C Preferred stock and $45,881 received from the exercise of common stock options and warrants. At September 30, 2016, we had cash of $150,454 compared to $953,234 at December 31, 2015. Our cash is held in bank deposit accounts. At September 30, 2016 and December 31, 2015, we had no convertible debentures outstanding.

Cash used in operations for the nine months ended September 30, 2016 and 2015 was $3,844,553 and $3,431,733, respectively, which represent cash outlays for research and development and general and administrative expenses in such periods. The increase in cash outlays principally resulted from additional in operating costs and general and administrative expenses net with an increase of our outstanding accounts payable by $202,534.

We used $12,095 cash for investing activities for the nine months ended September 30, 2016, compared to $11,583 for the nine months ended September 30, 2015.  During the nine months ended September 30, 2016 and 2015, we purchased office furniture and computer equipment of $12,095 and $8,971, respectively.  Additionally, in 2015, we paid a long term deposit of $2,612 for our corporate facility in Minneapolis.

In their report dated March 14, 2016, our independent registered public accounting firm stated at December 31, 2015, there is substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is an issue raised due to our net losses and negative cash flows from operations since inception and our expectation that these conditions will continue for the foreseeable future. In addition, we will require additional financing to fund future operations.

Further, we do not have any commercial products available for sale and have not generated revenues to date, and there is no assurance that, if approval of our products is received, we will be able to generate cash flow to fund operations. In addition, there can be no assurance that our research and development will be successfully completed or that any product will be approved or commercially viable. Our ability to continue as a going concern is subject to our ability to obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, obtaining loans from various financial institutions or being awarded grants from government agencies, where possible. Our continued net operating losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful.
 
We expect to incur losses from operations for the near future. We expect to incur increasing research and development expenses, including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as we expand our business development, add infrastructure and incur additional costs related to being a public company, including incremental audit fees, investor relations programs and increased professional services.

Our future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates, the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing and our success in developing markets for our product candidates. We believe our existing cash will not be sufficient to fund our operating expenses and capital equipment requirements. We anticipate we will need approximately $2 million in addition to our current cash on hand to fund our operating expenses and capital equipment requirements for the next 12 months.

We will have to raise additional funds to continue our operations and, while we have been successful in doing so in the past, there can be no assurance that we will be able to do so in the future. Our continuation as a going concern is dependent upon our ability to obtain necessary additional funds to continue operations and the attainment of profitable operations.
 
Future financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, existing holders of our securities may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our securities.
 
If additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.

Off-Balance Sheet Arrangements
 
We do not have any off-balance sheet arrangements.
 
Transactions with Related Parties

The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009.  No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. The net amount of outstanding advances at September 30, 2016 and December 31, 2015 was $-0-.

At September 30, 2016 and December 31, 2015, the Company had reimbursable travel and other related expenses due related parties of $8,703 and $12,716, respectively.


Critical Accounting Policies and Estimates
 
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

Research and Development.
 
We account for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.

Stock Based Compensation.
 
All stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted stock and stock options, which are measured at fair value on the grant date and recognized in the statements of operations as compensation expense over the relevant vesting period. Restricted stock payments and stock-based payments to nonemployees are recognized as an expense over the period of performance.

Such payments are measured at fair value at the earlier of the date a performance commitment is reached or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable, the measurement date is the date the award is issued.
 
On October 29, 2014, our common stock commenced trading on OTCQB under the symbol “BSGM.”  Fair value is typically determined by the closing price of our common stock on the date of the award.
 
Income Taxes.
 
Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. We record an estimated valuation allowance on our deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. We recognize a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

 
Derivative and Warrant Liabilities.

We account for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, we did not have any derivative instruments that were designated as hedges.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Not required under Regulation S-K for “smaller reporting companies.”

ITEM 4.  CONTROLS AND PROCEDURES
 
(a) Evaluation of disclosure controls and procedures.
 
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
 
Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2016, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
 
(b) Changes in internal control over financial reporting.
 
There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 1.  LEGAL PROCEEDINGS
 
None.

ITEM 1A.  RISK FACTORS
 
Not required under Regulation S-K for “smaller reporting companies.”

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
On September 1, 2016, we consummated one closing under the Unit Purchase Agreement, dated May 16, 2016, by and among certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 305,026 shares of our common stock and 152,513 warrants to purchase one share of our common stock, exercisable at a price of $1.95 per share and expiring August 30, 2019, in exchange for aggregate consideration of $431,549, net of $25,990 in expenses. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

On September 19, 2016, we consummated one closing under the Unit Purchase Agreement, dated May 16, 2016, by and among certain accredited investors (as defined by Rule 501 under the Securities Act of 1933, as amended), pursuant to which we issued 70,000 shares of our common stock and 35,000 warrants to purchase one share of our common stock, exercisable at a price of $1.95 per share and expiring September 19, 2019, in exchange for aggregate consideration of $98,533, net of $6,467 in expenses. The securities sold in this offering were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933, as amended.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
 
None.
 
ITEM 4.  MINE SAFETY DISCLOSURES
 
None.
 
ITEM 5.  OTHER INFORMATION
 
None.

ITEM 6.  EXHIBITS

31.01
 
 
31.02
 
 
32.01
 
 
101 INS
XBRL Instance Document
 
 
101 SCH
XBRL Taxonomy Extension Schema Document
 
 
101 CAL
XBRL Taxonomy Calculation Linkbase Document
 
 
101 DEF
XBRL Taxonomy Extension Definition Linkbase Document
 
 
101 LAB
XBRL Taxonomy Labels Linkbase Document
 
 
101 PRE
XBRL Taxonomy Presentation Linkbase Document



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
BIOSIG TECHNOLOGIES, INC.
 
 
 
Date: November 14, 2016
By:
/s/ GREGORY D. CASH
 
 
 
Gregory D. Cash
 
 
Chief Executive Officer (Principal Executive Officer)
 
 
 
 
 
 
Date: November 14, 2016
By:
/s/ STEVEN CHAUSSY
 
 
 
Steven Chaussy
 
 
Chief Financial Officer (Principal Financial Officer
 
 
and Principal Accounting Officer)

36
 
EX-31.01 2 ex31-01.htm EX-31.01
EXHIBIT 31.01
 
CERTIFICATION
 
I, Gregory D. Cash, certify that:
 
 
1.
I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
 
Date: November 14, 2016
 
/s/ GREGORY D. CASH
Gregory D. Cash
 Chief Executive Officer

 EX-31.02 3 ex31-02.htm EX-31.02
EXHIBIT 31.02
 
CERTIFICATION
 
I, Steven Chaussy, certify that:
 
 
1.
I have reviewed this quarterly report on Form 10-Q of BioSig Technologies, Inc..;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
 
Date: November 14, 2016
 
/s/ STEVEN CHAUSSY
Steven Chaussy
 Chief Financial Officer

 EX-32.01 4 ex32-01.htm EX-32.01
EXHIBIT 32.01
 
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Gregory D. Cash, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fiscal quarter ended September 30, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioSig Technologies, Inc.
 
 
 
 
 
 
 
 
By:
 
/s/ GREGORY D. CASH
  
Date: November 14, 2016
 
Name:
 
Gregory D. Cash
 
 
Title:
 
Chief Executive Officer
 
I, Steven Chaussy, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fiscal quarter ended September 30, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioSig Technologies, Inc.
 
 
 
 
 
 
 
 
By:
 
/s/ STEVEN CHAUSSY 
  
Date: November 14, 2016
 
Name:
 
Steven Chaussy
 
 
Title:
 
Chief Financial Officer

EX-101.INS 5 bsgm-20160930.xml XBRL INSTANCE DOCUMENT 0001530766 2016-09-30 0001530766 2015-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2016-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2015-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2016-09-30 0001530766 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2016-09-30 0001530766 us-gaap:SeriesBPreferredStockMember 2015-12-31 0001530766 2016-07-01 2016-09-30 0001530766 2015-07-01 2015-09-30 0001530766 2016-01-01 2016-09-30 0001530766 2015-01-01 2015-09-30 0001530766 us-gaap:CommonStockMember 2015-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001530766 us-gaap:RetainedEarningsMember 2015-12-31 0001530766 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-09-30 0001530766 bsgm:SettlementOfSeriesCPreferredStockAndAccruedDividendsMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001530766 bsgm:SettlementOfSeriesCPreferredStockAndAccruedDividendsMember us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001530766 bsgm:SettlementOfSeriesCPreferredStockAndAccruedDividendsMember us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-09-30 0001530766 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001530766 us-gaap:CommonStockMember 2016-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001530766 us-gaap:RetainedEarningsMember 2016-09-30 0001530766 us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001530766 bsgm:SettlementOfSeriesCPreferredStockAndAccruedDividendsMember us-gaap:SeriesCPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001530766 2014-12-31 0001530766 2015-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2015-01-01 2015-09-30 0001530766 2016-11-14 0001530766 us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0001530766 bsgm:WorkingCaptialExcludingDerivativeAndWarrantLiabiltiesMember 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2015-12-31 0001530766 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001530766 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001530766 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001530766 us-gaap:MinimumMember 2016-01-01 2016-09-30 0001530766 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001530766 us-gaap:ComputerEquipmentMember 2016-09-30 0001530766 us-gaap:ComputerEquipmentMember 2015-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2016-09-30 0001530766 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2013-01-09 0001530766 us-gaap:SeriesCPreferredStockMember 2013-01-09 2013-01-09 0001530766 bsgm:FullRatchetAntiDilutionProtectionProvisionMember us-gaap:SeriesCPreferredStockMember 2013-01-09 0001530766 bsgm:EmbeddedBeneficialConversionFeatureMember us-gaap:SeriesCPreferredStockMember 2013-01-09 2013-12-31 0001530766 us-gaap:WarrantMember us-gaap:SeriesCPreferredStockMember 2013-01-09 2013-12-31 0001530766 bsgm:EmbeddedBeneficialConversionFeatureMember us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 us-gaap:WarrantMember us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 bsgm:IssuanceCostsMember us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2013-12-31 0001530766 2013-01-01 2013-12-31 0001530766 us-gaap:BridgeLoanMember us-gaap:SeriesCPreferredStockMember 2013-02-06 2013-02-06 0001530766 us-gaap:SeriesCPreferredStockMember 2013-02-01 2013-07-31 0001530766 2015-03-31 0001530766 us-gaap:WarrantMember 2015-03-31 0001530766 us-gaap:MinimumMember 2015-01-01 2015-03-31 0001530766 us-gaap:MaximumMember 2015-01-01 2015-03-31 0001530766 2015-01-01 2015-03-31 0001530766 2016-02-01 2016-02-29 0001530766 us-gaap:SeriesCPreferredStockMember 2016-02-01 2016-02-29 0001530766 2016-05-01 2016-05-31 0001530766 us-gaap:SeriesCPreferredStockMember 2016-05-01 2016-05-31 0001530766 2016-06-01 2016-06-30 0001530766 us-gaap:SeriesCPreferredStockMember 2016-06-01 2016-06-30 0001530766 us-gaap:MinimumMember us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-09-30 0001530766 us-gaap:MaximumMember us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-09-30 0001530766 2014-01-01 2014-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2016-09-30 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2016-01-01 2016-09-30 0001530766 bsgm:EquityIncentive2012PlanMember 2016-01-01 2016-09-30 0001530766 bsgm:EquityIncentive2012PlanMember 2016-09-30 0001530766 bsgm:ServicesProvidedMember 2016-01-01 2016-09-30 0001530766 bsgm:ServicesProvidedMember 2016-09-30 0001530766 2015-10-23 2015-10-23 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2012-10-19 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2012-10-19 2012-10-19 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember us-gaap:MaximumMember 2012-10-19 2012-10-19 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember bsgm:OfficersDirectorsAndKeyConsultantsMember 2016-01-01 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2016-09-01 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2016-08-24 2016-08-24 0001530766 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-08-24 2016-08-24 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-08-24 2016-08-24 0001530766 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2016-08-24 2016-08-24 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2016-07-01 2016-09-30 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2015-07-01 2015-09-30 0001530766 us-gaap:EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2015-01-01 2015-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2016-09-07 2016-09-07 0001530766 us-gaap:RestrictedStockMember 2016-07-01 2016-09-30 0001530766 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001530766 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001530766 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001530766 us-gaap:RestrictedStockMember 2016-09-30 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-02-09 2016-02-09 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-02-09 0001530766 bsgm:WarrantsAt1.95Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-02-09 2016-02-09 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-02-09 2016-02-09 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-02-09 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-03-09 2016-03-09 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-03-09 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-03-09 2016-03-09 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-03-09 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-04-01 2016-04-01 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-04-01 0001530766 bsgm:WarrantsAt1.95Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-04-01 2016-04-01 0001530766 bsgm:WarrantsAt1.95Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-04-01 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-04-19 2016-04-19 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-04-19 0001530766 bsgm:WarrantsAt1.95Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-04-19 2016-04-19 0001530766 bsgm:WarrantsAt1.95Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-04-19 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-04-29 2016-04-29 0001530766 bsgm:WarrantsAt1.95Member us-gaap:PrivatePlacementMember 2016-04-29 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-04-29 2016-04-29 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:PrivatePlacementMember 2016-04-29 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:MinimumMember us-gaap:PrivatePlacementMember 2016-04-29 2016-04-29 0001530766 bsgm:WarrantsAt1.50Member bsgm:WarrantsIssuedToPlacementAgentsMember us-gaap:MaximumMember us-gaap:PrivatePlacementMember 2016-04-29 2016-04-29 0001530766 bsgm:WarrantsAt210Member us-gaap:WarrantMember 2016-06-01 2016-06-01 0001530766 bsgm:WarrantsAt210Member us-gaap:WarrantMember 2016-06-01 0001530766 bsgm:WarrantsAt1.95Member us-gaap:WarrantMember 2016-08-30 2016-08-30 0001530766 bsgm:WarrantsAt1.95Member us-gaap:WarrantMember 2016-08-30 0001530766 bsgm:WarrantsAt1.95Member us-gaap:WarrantMember 2016-09-19 2016-09-19 0001530766 bsgm:WarrantsAt1.95Member us-gaap:WarrantMember 2016-09-19 0001530766 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001530766 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001530766 bsgm:ServicesProvidedMember 2015-07-01 2015-09-30 0001530766 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001530766 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2016-09-30 0001530766 bsgm:OptionsAt1.01To2.00Member 2016-01-01 2016-09-30 0001530766 bsgm:OptionsAt1.01To2.00Member 2016-09-30 0001530766 bsgm:OptionsAt2.01To3.00Member 2016-01-01 2016-09-30 0001530766 bsgm:OptionsAt2.01To3.00Member 2016-09-30 0001530766 bsgm:OptionsAt3.01To4.00Member 2016-01-01 2016-09-30 0001530766 bsgm:OptionsAt3.01To4.00Member 2016-09-30 0001530766 2015-01-01 2015-12-31 0001530766 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001530766 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001530766 us-gaap:RestrictedStockMember 2015-12-31 0001530766 bsgm:WarrantsAt0.001Member 2016-09-30 0001530766 bsgm:WarrantsAt0.001Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt1.50Member 2016-09-30 0001530766 bsgm:WarrantsAt1.50Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt1.84Member 2016-09-30 0001530766 bsgm:WarrantsAt1.84Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt1.95Member 2016-09-30 0001530766 bsgm:WarrantsAt1.95Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt2_00Member 2016-09-30 0001530766 bsgm:WarrantsAt2_00Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt2.02Member 2016-09-30 0001530766 bsgm:WarrantsAt2.02Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt210Member 2016-09-30 0001530766 bsgm:WarrantsAt210Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt2.50Member 2016-09-30 0001530766 bsgm:WarrantsAt2.50Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt2.75Member 2016-09-30 0001530766 bsgm:WarrantsAt2.75Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt3.67Member 2016-09-30 0001530766 bsgm:WarrantsAt3.67Member 2016-01-01 2016-09-30 0001530766 bsgm:WarrantsAt3.75Member 2016-09-30 0001530766 bsgm:WarrantsAt3.75Member 2016-01-01 2016-09-30 0001530766 us-gaap:WarrantMember 2016-09-30 0001530766 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001530766 us-gaap:WarrantMember 2015-12-31 0001530766 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2015-12-31 0001530766 us-gaap:SubsequentEventMember 2016-10-16 2016-10-16 0001530766 us-gaap:SubsequentEventMember 2016-10-28 2016-10-28 0001530766 us-gaap:SubsequentEventMember 2016-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 150454 953234 134530 31308 284984 984542 22692 18408 27612 27612 335288 1030562 426497 223546 341403 340291 2324460 1621199 291086 285157 3383446 2470193 1090000 1471000 0 0 20935 16826 38295183 29314399 -42454276 -32241856 -4138158 -2910631 335288 1030562 8703 12716 1090 1471 1090 1471 1090000 1471000 0.001 0.001 1000000 1000000 200 200 600 600 4200 4200 0.001 0.001 50000000 50000000 20935093 16825703 20935093 16825703 560514 354471 2139671 1146113 991852 2117010 7257852 8801878 2570 2607 7811 7948 1554936 2474088 9405334 9955939 -1554936 -2474088 -9405334 -9955939 17771 2851755 -807087 3050318 0 0 1 -1298 0 0 0 529704 17771 2851755 -807086 2519316 -1537165 377667 -10212420 -7436623 0 0 0 0 -1537165 377667 -10212420 -7436623 24726 53048 85467 244516 -1561891 324619 -10297887 -7681139 -0.08 0.02 -0.55 -0.57 20581041 14849127 18847515 13565453 16825703 16826 29314399 -32241856 2208514 2208 3051660 3053868 1335000 1335 2469715 2471050 254000 254 380746 381000 53331 53 84302 84355 97897 97897 258545 259 2981931 2982190 85467 -10212420 20935093 20935 38295183 -42454276 1.50 1.58 0 585324 5453240 6907423 103222 8141 202534 -213754 0 -226305 -417 -2713 -3844553 -3431733 12095 8971 0 2612 -12095 -11583 3053868 3042213 0 450000 0 20900 0 24981 3053868 3538094 -802780 94778 953234 239781 150454 334559 0 1298 0 0 465355 1654811 BIOSIG TECHNOLOGIES, INC. 10-Q --12-31 20950093 false 0001530766 Yes No Smaller Reporting Company No 2016 Q3 2016-09-30 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">NOTE 1 &#x2013;&#160;NATURE OF OPERATIONS AND BASIS OF PRESENTATION</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">BioSig Technologies Inc. (the &#x201c;Company&#x201d;) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The condensed balance sheet as of December 31, 2015 has been derived from audited financial statements.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015 filed with the Company&#x2019;s Form 10-K with the Securities and Exchange Commission on March 14, 2016.</div><br/> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">NOTE 2 &#x2013;GOING CONCERN AND MANAGEMENT&#x2019;S LIQUIDITY PLANS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">As of September 30, 2016, the Company had cash of $150,454&#160;and working capital deficit (current liabilities in excess of current assets) of $3,098,462 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised approximately $450,000 in October 2016 through the sale of common stock and warrants (See Note 11). As of September 30, 2016, excluding the derivative and warrant liabilities, the Company's working capital deficit would have been $482,916.&#160;During the nine months ended September 30, 2016, the Company used net cash in operating activities of $3,844,553.&#160; These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 2 months.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company's primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders' deficiencies at September 30, 2016 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Accordingly, the accompanying condensed financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.</div><br/> -3098462 450000 482916 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">NOTE&#160;3 &#x2013;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Use of estimates</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company&#x2019;s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Fair Value of Financial Instruments</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#x201c;ASC 820-10&#x201d;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;), which permits entities to choose to measure many financial instruments and certain other items at fair value.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Derivative Instrument Liability</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Research and development costs</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514&#160;and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Net Earnings (Loss) Per Common Share</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.&#160;&#160;Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or &#x201c;if converted&#x201d; methods as applicable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company&#x2019;s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:</div><br/><table id="z82edfcbef2474cec8cb3abbc9c7d935e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">726,667</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,238,667</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,405,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,372,677</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">17,150,092</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">16,474,467</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Stock Based Compensation</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Income Taxes</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate.&#160;&#160;Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Registration Rights</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (&#x201c;ASC 825-20&#x201d;). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists,&#160;to record or adjust the liability to current period operations.&#160;&#160;On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.&#160;&#160;As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors&#160;pursuant to which the Company sold to the investors units, which each unit&#160;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#160;&#160;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#160;&#160;The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on April 29, 2016. On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Reclassification</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Certain reclassifications have been made to prior periods&#x2019; data to conform with the current year&#x2019;s presentation. These reclassifications had no effect on reported income or losses.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Recent Accounting Pronouncements</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Subsequent Events</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.&#160; Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.</div><br/> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Use of estimates</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company&#x2019;s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Fair Value of Financial Instruments</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (&#x201c;ASC 820-10&#x201d;) and Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;), which permits entities to choose to measure many financial instruments and certain other items at fair value.</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Derivative Instrument Liability</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Research and development costs</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514&#160;and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively.</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Net Earnings (Loss) Per Common Share</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.&#160;&#160;Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or &#x201c;if converted&#x201d; methods as applicable.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company&#x2019;s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:</div><br/><table id="z82edfcbef2474cec8cb3abbc9c7d935e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">726,667</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,238,667</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,405,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,372,677</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">17,150,092</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">16,474,467</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Stock Based Compensation</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested.</div> 8090190 6745099 7780190 5613501 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Income Taxes</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (&#x201c;ASC 740-10&#x201d;) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate.&#160;&#160;Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Registration Rights</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (&#x201c;ASC 825-20&#x201d;). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists,&#160;to record or adjust the liability to current period operations.&#160;&#160;On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.&#160;&#160;As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors&#160;pursuant to which the Company sold to the investors units, which each unit&#160;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#160;&#160;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#160;&#160;The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on April 29, 2016. On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.</div> 55620 0 0 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Reclassification</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Certain reclassifications have been made to prior periods&#x2019; data to conform with the current year&#x2019;s presentation. These reclassifications had no effect on reported income or losses.</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Recent Accounting Pronouncements</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</div> <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Subsequent Events</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.&#160; Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.</div> Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:<br /><br /><table id="z82edfcbef2474cec8cb3abbc9c7d935e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Series C convertible preferred stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">726,667</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,238,667</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Options to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,405,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Warrants to purchase common stock</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,372,677</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Totals</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">17,150,092</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">16,474,467</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 726667 1238667 8090190 7405190 8333235 6372677 17150092 16474467 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">NOTE&#160;4 &#x2013; PROPERTY AND EQUIPMENT</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows:</div><br/><table id="z24a999bccc6d455084a3a6e6e0e14974" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Computer equipment</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">80,544</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">68,449</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Furniture and fixtures</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">10,117</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">10,117</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Subtotal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">90,661</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">78,566</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Less accumulated depreciation</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(67,969</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(60,158</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Property and equipment, net</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">22,692</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">18,408</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Depreciation expense was $2,570 and $7,811 for the three and nine months ended September 30, 2016, respectively; and $2,607 and $7,948 for the three and nine months ended September 30, 2015, respectively.</div><br/> P3Y P5Y Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows:<br /><br /><table id="z24a999bccc6d455084a3a6e6e0e14974" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Computer equipment</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">80,544</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">68,449</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Furniture and fixtures</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">10,117</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">10,117</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Subtotal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">90,661</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">78,566</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Less accumulated depreciation</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(67,969</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(60,158</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Property and equipment, net</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">22,692</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">18,408</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 80544 68449 10117 10117 90661 78566 67969 60158 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">NOTE&#160;5&#160;&#x2013; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following:</div><br/><table id="z9654faff8bcc4dd58e21cae5f609faef" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued accounting and legal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">185,630</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">112,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued reimbursements</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">13,613</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued consulting</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,500</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">15,200</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued research and development expenses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">177,577</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">34,179</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued office and other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">31,482</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued payroll</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">35,835</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Deferred rent</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,432</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,016</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued settlement related to arbitration</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">426,497</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">223,546</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/> Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following:<br /><br /><table id="z9654faff8bcc4dd58e21cae5f609faef" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued accounting and legal</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">185,630</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">112,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued reimbursements</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">13,613</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued consulting</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,500</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">15,200</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued research and development expenses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">177,577</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">34,179</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued office and other</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">31,482</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued payroll</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">35,835</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Deferred rent</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,432</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,016</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Accrued settlement related to arbitration</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">13,333</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">426,497</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">223,546</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 185630 112723 0 13613 3500 15200 177577 34179 7190 31482 35835 0 3432 3016 13333 13333 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE&#160;6&#160;&#x2013; SERIES C 9% CONVERTIBLE PREFERRED STOCK</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On January 9,&#160;2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the &#x201c;Series C Preferred Stock&#x201d;).</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.&#160;&#160;The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.&#160;&#160;The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.&#160;&#160;The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:</div><br/><table id="z69da4570744c472fa66e6afe40ca1c9e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">incur additional indebtedness;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">permit liens on assets;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">pay cash dividends to our stockholders; and</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 3.66%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">&#x25cf;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 96.34%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">engage in transactions with affiliates.</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share.&#160;The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In the event that:</div><br/><table id="zb08463ee22244b9790bc8d91b18f8b1b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">&#160;&#160;(i)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">(ii)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">(iii)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">&#160;(iv)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">(v)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we are party to a change of control transaction,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">(vi)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we file for bankruptcy or a similar arrangement or are adjudicated insolvent,</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top; WIDTH: 4.76%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">(vii)&#160;&#160;</div> </td> <td style="VERTICAL-ALIGN: top; WIDTH: 95.24%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.&#160;&#160;&#160;The Company determined that certain of the defined triggering events were outside the Company&#x2019;s control and therefore classified the Series C Preferred Stock outside of equity.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company&#x2019;s common stock at $2.61 per share expiring five years from the initial exercise date.&#160;&#160;The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a &#x201c;cashless exercise&#x201d;.&#160;</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the&#160;intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.&#160;&#160;The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671),&#160;the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company&#x2019;s Series C Preferred Stock.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company&#x2019;s Series C Preferred Stock for net proceeds of $1,814,910.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the &#x201c;readily convertible to cash&#x201d; as described in Accounting Standards Codification 815 and therefore bifurcation is not required.&#160;&#160;There was no established market for the Company&#x2019;s common stock.&#160;&#160;As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company&#x2019;s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">For the nine months ended September 30, 2016, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $97,897 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.23% to 0.59%, a dividend yield of 0%, and volatility of 141% to 150%.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Series C Preferred Stock issued and outstanding totaled 1,090 and 1,471 as of September30, 2016 and December 31, 2015, respectively.&#160;&#160;As of September 30, 2016 and December 31, 2015, the Company has accrued $341,403 and $340,291 dividends payable on the Series C Preferred Stock.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Registration Rights Agreement</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In connection with the Company&#x2019;s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.&#160;&#160;As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement as of December 31, 2014. At December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.</div><br/> 4200 0.09 1000 payable quarterly The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:&#x25cf;incur additional indebtedness;&#x25cf;permit liens on assets;&#x25cf;repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;&#x25cf;pay cash dividends to our stockholders; and&#x25cf;engage in transactions with affiliates. Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:(i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v) we are party to a change of control transaction,(vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%. 1.50 1330627 2.61 P5Y after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a &#x201c;cashless exercise&#x201d;. 1.50 2315301 1303671 1064739 1303671 1064739 412590 2781000 P1Y 600 2181 1814910 1242590 4097444 P2Y284D P3Y6M 0.0056 0.0089 0.00 1.4100 54859 75 197714 236 54759 70 97897 P2Y 0.0023 0.0059 0.00 1.41 1.50 the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE&#160;7&#160;&#x2013; WARRANT AND DERIVATIVE LIABILITIES</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the &#x201c;readily convertible to cash&#x201d; as described in Accounting Standards Codification 815 and therefore bifurcation was not required.&#160;&#160;There was no established market for the Company&#x2019;s common stock.&#160;&#160;&#160;As of March 31, 2015, the Company determined a market had been established for the Company&#x2019;s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company valued the reset provisions of the Series C Preferred Stock&#160;and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">At September 30, 2016, the Company marked to market the fair value of the reset provisions of the Series C Preferred Stock and warrants and determined fair values of $291,086 and $2,324,460, respectively. The Company recorded a gain(loss) from change in fair value of derivatives of $17,771 and $(807,087) for the three and nine months ended September 30, 2016. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 0.49 to 3.61 years, a risk free interest rate of 0.39% to 1.01%, a dividend yield of 0%, and volatility of 143.00% to 152.00%.</div><br/> 4097444 291086 P178D P3Y222D 0.0039 0.0101 0.00 1.4300 1.5200 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE 8&#160;&#x2013; STOCKHOLDER EQUITY</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Preferred stock</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company is authorized to issue 1,000,000 shares of&#160;$0.001 par value preferred stock. As of September 30, 2016 and December 31, 2015,&#160;the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 shares of Series C Preferred Stock. As of September 30, 2016 and December 31, 2015, there were no outstanding shares of Series A and Series B preferred stock.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In February 2016, the Company issued 54,859&#160;shares of its common stock in exchange for 75 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company&#x2019;s Series C Preferred Stock and accrued dividends.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of September 30, 2016 and December 31, 2015, the Company has 1,090 and 1,471 Series C Preferred Stock issued and outstanding.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Common stock</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of September 30, 2016 and December 31, 2015, the Company had 20,935,093 and 16,825,703 shares issued and outstanding, respectively.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share).</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company issued an aggregate of 545,000 shares of common stock&#160; for services rendered totaling $1,051,850 ($1.93 average per share).</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,208,514 shares of common stock and 1,254,550 warrants for aggregate proceeds of $3,053,868, net of $278,188 in expenses.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company issued 175,000 shares of common stock as vested previously issued restricted stock units</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.&#160; The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:&#160; dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company&#x2019;s common stock: $1.84.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit&#160;consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock (the &#x201c;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Private Placement</font>&#x201d;).&#160;&#160;In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.&#160;</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter.&#160;&#160;The final closing under the Private Placement occurred on April 29, 2016.&#160;&#160;On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.</div><br/> 790000 1419200 1.80 545000 1051850 1.93 2208514 1254550 3053868 278188 175000 83545 100000 0.00 1.2282 0.0108 P5Y 1.84 each unit consisting of one share of the Company&#x2019;s common stock and a warrant to purchase one half of one share of common stock The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter. <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE 9&#160;&#x2013; OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Options</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On October 19, 2012, the Company&#x2019;s Board of Directors approved the 2012 Equity Incentive Plan (&#x201c;the &#x201c;Plan) and terminated the Long-Term Incentive Plan (the &#x201c;2011 Plan&#x201d;). The Plan provides for the issuance of options to purchase up to 11,686,123 (as amended)&#160;shares of the Company&#x2019;s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers,&#160;directors and key consultants.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company granted an aggregate of 873,545 stock grants to officers, employees and key consultants under the plan. See Note 8.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The following table presents information related to stock options at September 30, 2016:</div><br/><table id="z21a6e8d2b48b43169d4c31fe92511357" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="11"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Remaining Life</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">In Years</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.01-2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2,139,642</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.8</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,572,642</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.01-3.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5,650,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5.6</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">4,872,457</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.01-4.00</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8.5</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,745,099</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">A summary of the stock option&#160;activity and related information for the Plan for the nine months ended September 30, 2016 is as follows:</div><br/><table id="z8367b2865ac646aa97c43754e485ceaf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,780,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.30</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.4</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">750,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.80</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Forfeiture/Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(440,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.24</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.26</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">12,350</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercisable at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,745,099</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.31</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,563</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company&#x2019;s stock price of $1.52 as of September 30, 2016, which would have been received by the option holders had those option holders exercised their options as of that date.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from using the Company&#x2019;s historical stock prices for 2016.&#160;Prior to 2016, the Company derived the volatility figure from an index of historical stock prices for comparable entities. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the &#x201c;simplified&#x201d; method, which is used for &#x201c;plain-vanilla&#x201d; options, as defined in the accounting standards codification.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.&#160;</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company&#x2019;s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company&#x2019;s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company estimated forfeitures related to option grants at a weighted average annual rate of&#160; 0% per year, as the Company does not yet have adequate historical data, for options granted during the nine months ended September 30, 2016 and 2015.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015:</div><br/><table id="z8b419094ea05493c9167491c57295e3e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1.08% - 1.69</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1.19% - 2.37</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">122.82</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">118.56% -130.30</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">5 &#x2013; 10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">7-10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">2.41</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">During the nine months ended September 30, 2016, the Company granted an aggregate of&#160; 685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.&#160; The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:&#160; dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company&#x2019;s common stock: $1.84.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The fair value of all options vesting during the three and nine months ended September 30, 2016 of $218,085 and $2,512,886, respectively, and during the three and nine months ended September 30, 2015 of $836,425 and $3,793,152, respectively, was charged to current period operations.&#160;&#160;Unrecognized compensation expense of $406,988 at September 30, 2016 will be expensed in future periods.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Restricted Stock</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The following table summarizes the restricted stock activity for the nine months ended September 30, 2016:</div><br/><table id="z01fe2968e3774d7f9774182b3d452650" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Restricted shares issued as of January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">175,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Granted</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr style="HEIGHT: 14px"> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Vested</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(175,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Total restricted shares issued as of September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Vested restricted shares as of September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Unvested restricted shares as of September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On September 7, 2016, the Company granted 180,000 restricted stock units (&#x201c;RSU&#x201d;) to a consultant vesting monthly over one year beginning October 7, 2016.<br /> </div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Stock based compensation expense related to restricted stock grants was $70,753 and $124,139 for the three months ended September 30, 2016, respectively; and $100,492 and $238,122 for the three and nine months ended September 30, 2015, &#160;respectively.&#160;As of September 30, 2016, the stock-based compensation relating to restricted stock of $202,847 remain unamortized and is expected to be amortized over the remaining period of approximately 1 year.&#160;&#160;&#160;&#160;</div><br/><div style="FONT-STYLE: italic">Warrants</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016:&#160;</div><br/><table id="z9062da84c85e4e3eab409ef6269f504d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Number</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Expiration</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 40%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Date</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">0.001</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">383,320</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">4,173,017</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">February 2018 to May 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.84</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">35,076</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.95</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,689,026</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">October 2018 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">30,755</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.10</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">38,572</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">June 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">228,720</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">August 2019 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.67</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">214,193</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">December 2018 to January 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.75</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,340,556</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">April 2019 to March 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On February 9, 2016, the Company issued 25,000 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 6,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 12,000 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 18,040 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued 17,996 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company&#x2019;s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company&#x2019;s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company&#x2019;s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company&#x2019;s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company&#x2019;s common stock.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Stock based compensation related to warrants issued for services was $641 and $56,930 for the three and nine months ended September 30, 2016, respectively; and $44,464 for the three and nine months ended September 30, 2015.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">A summary of the warrant&#160;activity for the nine months ended September 30, 2016 is as follows:</div><br/><table id="zdc7df0343cbe44929df03d9b51ee0f69" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,078,685</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">497,933</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,254,550</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.90</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.5</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.3</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">665,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Vested and expected to vest at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.3</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">665,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercisable at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.3</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">665,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company&#x2019;s stock price of $1.52 as of September 30, 2016, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.</div><br/> 11686123 the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. P10Y 227388 750000 100000 873545 1.52 0.00 1.84 P10Y 83545 100000 0.00 1.2282 0.0108 P5Y 1.84 65000 1.33 P10Y 12500 37500 15000 218085 2512886 836425 3793152 406988 180000 P1Y 70753 124139 100492 238122 202847 P1Y 25000 1.95 2019-02-09 6000 1.50 2019-02-09 100000 1.95 2019-03-09 12000 1.50 2019-03-09 100327 1.95 2019-04-01 18040 1.50 2019-04-01 84980 1.95 2019-04-19 17996 1.50 2019-04-19 567866 1.95 2019-04-29 96256 1.50 2018-10-23 2019-04-29 38572 2.10 2019-06-01 152513 1.95 35000 1.95 641 56930 44464 9 1.52 The following table presents information related to stock options at September 30, 2016:<br /><br /><table id="z21a6e8d2b48b43169d4c31fe92511357" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="11"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercisable</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Remaining Life</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Number of</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">In Years</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Options</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.01-2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2,139,642</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.8</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,572,642</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.01-3.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5,650,548</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5.6</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">4,872,457</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.01-4.00</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8.5</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">300,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,745,099</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 1.01 2.00 2139642 P6Y292D 1572642 2.01 3.00 5650548 P5Y219D 4872457 3.01 4.00 300000 P8Y6M 300000 8090190 P6Y 6745099 A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2016 is as follows:<br /><br /><table id="z8367b2865ac646aa97c43754e485ceaf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,780,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.30</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.4</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">750,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.80</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">10.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Forfeiture/Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(440,000</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.24</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,090,190</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.26</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">12,350</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercisable at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6,745,099</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.31</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3,563</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 7780190 2.30 P6Y146D 0 750000 1.80 P10Y 0 440000 2.24 2.26 12350 6745099 2.31 P6Y 3563 The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015:<br /><br /><table id="z8b419094ea05493c9167491c57295e3e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">September 30,</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Risk-free interest rate</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1.08% - 1.69</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1.19% - 2.37</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Dividend yield</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">0</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Stock price volatility</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">122.82</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">118.56% -130.30</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">%</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Expected life</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">5 &#x2013; 10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; " valign="bottom" colspan="3"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">7-10 years</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; "> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Weighted average grant date fair value</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">$</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 11%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">2.41</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> </table> 0.0108 0.0169 0.0119 0.0237 0.00 1.1856 1.3030 P5Y P10Y P7Y P10Y 1.50 2.41 The following table summarizes the restricted stock activity for the nine months ended September 30, 2016:<br /><br /><table id="z01fe2968e3774d7f9774182b3d452650" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Restricted shares issued as of January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">175,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Granted</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr style="HEIGHT: 14px"> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Vested</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(175,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Total restricted shares issued as of September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Vested restricted shares as of September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 61%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Unvested restricted shares as of September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">180,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 175000 180000 175000 180000 0 180000 The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016:<br /><br /><table id="z9062da84c85e4e3eab409ef6269f504d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Number</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Expiration</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Outstanding</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 40%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Date</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">0.001</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">383,320</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">4,173,017</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">February 2018 to May 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.84</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">35,076</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.95</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,689,026</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">October 2018 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">30,755</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">January 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.10</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">38,572</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">June 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.50</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">100,000</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">August 2018</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.75</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">228,720</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">August 2019 to September 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.67</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">214,193</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">December 2018 to January 2019</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.75</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 15%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,340,556</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 40%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">April 2019 to March 2020</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 15%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 40%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> </tr> </table> 0.001 383320 January 2020 1.50 4173017 February 2018 to May 2020 1.84 35076 January 2020 1.95 1689026 October 2018 to September 2019 2.00 100000 August 2018 2.02 30755 January 2020 2.10 38572 June 2019 2.50 100000 August 2018 2.75 228720 August 2019 to September 2019 3.67 214193 December 2018 to January 2019 3.75 1340556 April 2019 to March 2020 8333235 A summary of the warrant activity for the nine months ended September 30, 2016 is as follows:<br /><br /><table id="zdc7df0343cbe44929df03d9b51ee0f69" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Weighted-Average</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Remaining</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Aggregate</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Shares</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Exercise Price</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Contractual Term</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Intrinsic Value</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at January 1, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7,078,685</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.02</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.0</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">497,933</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Grants</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,254,550</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.90</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.5</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercised</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Canceled</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Outstanding at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.3</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">665,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Vested and expected to vest at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.3</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">665,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 44%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Exercisable at September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8,333,235</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.00</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.3</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">665,723</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> </table> 7078685 2.02 P3Y 497933 1.90 P2Y6M 0 0 2.00 P2Y109D 665723 8333235 2.00 P2Y109D 665723 8333235 2.00 P2Y109D 665723 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE&#160;10&#160;&#x2013; FAIR VALUE MEASUREMENT</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (&#x201c;ASC 825-10&#x201d;). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Level 2 &#x2013; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Level 3 &#x2013; Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The carrying value of the Company&#x2019;s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of September 30, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1 or 2 disclosures.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">As of September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The derivative and warrant liability as of September 30, 2016, in the amount of $291,086 and $2,324,460, respectively, has a level 3 classification.</div><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The following table provides a summary of changes in fair value of the Company&#x2019;s level 3 financial liabilities as of September 30, 2016:</div><br/><table id="z37d0413510ec464e83bfa6edbe2dff72" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Warrant</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Liability</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Derivative</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Balance, December 31, 2015</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,621,199</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">285,157</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Total (gains) losses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Transfers out due to conversion of Series C Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(97,897</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Mark to market to September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">703,261</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">103,826</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Balance, September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2,324,460</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">291,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(703,261</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(103,826</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> </table><br/><div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Fluctuations in the Company&#x2019;s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company&#x2019;s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company&#x2019;s derivative instruments.</div><br/> The following table provides a summary of changes in fair value of the Company&#x2019;s level 3 financial liabilities as of September 30, 2016:<br /><br /><table id="z37d0413510ec464e83bfa6edbe2dff72" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%; text-align: center;" cellspacing="0" cellpadding="0"> <tr> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 47%" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Warrant</div> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Liability</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Derivative</div> </td> <td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Balance, December 31, 2015</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1,621,199</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">285,157</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Total (gains) losses</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Transfers out due to conversion of Series C Preferred Stock</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">-</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(97,897</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Mark to market to September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">703,261</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">103,826</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Balance, September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2,324,460</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">291,086</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff; white-space: nowrap;" valign="bottom">&#160;</td> </tr> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 47%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(703,261</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; " valign="bottom">&#160;</td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">$</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; " valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(103,826</div> </td> <td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; white-space: nowrap;" valign="bottom"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">)</div> </td> </tr> </table> 1621199 285157 0 97897 -703261 -103826 2324460 291086 -703261 -103826 <div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">NOTE 11 &#x2013; SUBSEQUENT EVENTS</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On October 16, 2016, the Company issued 15,000 shares of its common stock to a consultant for services rendered valued at $22,800. </div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On&#160;October 28, 2016, the Company entered into securities purchase agreements with investors, pursuant to which the Company received from subscriptions for the purchase of&#160;346,567 shares of the Company&#x2019;s common stock and warrants to purchase 173,284 shares of our common stock at $1.50, expiring&#160;three years from issuance, for aggregate net cash proceeds of $450,477, after financing costs of $69,373.</div><br/> 15000 22800 346567 173284 1.50 P3Y 450477 69373 EX-101.SCH 6 bsgm-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - NOTE 8 - STOCKHOLDER EQUITY link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - NOTE 8 - STOCKHOLDER EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 bsgm-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 bsgm-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 bsgm-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 bsgm-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document And Entity Information - shares
 9 Months Ended
Sep. 30, 2016
Nov. 14, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name BIOSIG TECHNOLOGIES, INC.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   20,950,093
Amendment Flag false  
Entity Central Index Key 0001530766  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Filer Category Smaller Reporting Company  
Entity Well-known Seasoned Issuer No  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED BALANCE SHEETS - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash $ 150,454 $ 953,234
Prepaid expenses 134,530 31,308
Total current assets 284,984 984,542
Property and equipment, net 22,692 18,408
Other assets:    
Deposits 27,612 27,612
Total assets 335,288 1,030,562
Current liabilities:    
Accounts payable and accrued expenses, including $8,703 and $12,716 to related parties as of September 30, 2016 and December 31, 2015, respectively 426,497 223,546
Dividends payable 341,403 340,291
Warrant liability 2,324,460 1,621,199
Derivative liability 291,086 285,157
Total current liabilities 3,383,446 2,470,193
Series C Preferred Stock, 1,090 and 1,471 shares issued and outstanding; liquidation preference of $1,090,000 and $1,471,000 as of September 30, 2016 and December 31, 2015, respectively 1,090,000 1,471,000
Stockholders’ deficit    
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock 0 0
Common stock, $0.001 par value, authorized 50,000,000 shares, 20,935,093 and 16,825,703 issued and outstanding as of September 30, 2016 and December 31, 2015, respectively 20,935 16,826
Additional paid in capital 38,295,183 29,314,399
Accumulated deficit (42,454,276) (32,241,856)
Total stockholders’ deficit (4,138,158) (2,910,631)
Total liabilities and stockholders’ deficit $ 335,288 $ 1,030,562
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Accounts payable and accrued expenses, related parties (in Dollars) $ 8,703 $ 12,716
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 20,935,093 16,825,703
Common stock, shares outstanding 20,935,093 16,825,703
Series C Preferred Stock [Member]    
Preferred stock, shares issued 1,090 1,471
Preferred stock, shares outstanding 1,090 1,471
Preferred stock, liquidation preference (in Dollars) $ 1,090,000 $ 1,471,000
Preferred stock, shares authorized 4,200 4,200
Series A Preferred Stock [Member]    
Preferred stock, shares authorized 200 200
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 600 600
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Operating expenses:        
Research and development $ 560,514 $ 354,471 $ 2,139,671 $ 1,146,113
General and administrative 991,852 2,117,010 7,257,852 8,801,878
Depreciation 2,570 2,607 7,811 7,948
Total operating expenses 1,554,936 2,474,088 9,405,334 9,955,939
Loss from operations (1,554,936) (2,474,088) (9,405,334) (9,955,939)
Other income (expense):        
Gain (loss) on change in fair value of derivatives 17,771 2,851,755 (807,087) 3,050,318
Interest income (expense) 0 0 1 (1,298)
Financing costs 0 0 0 (529,704)
Total other income (expense) 17,771 2,851,755 (807,086) 2,519,316
(Loss) income before income taxes (1,537,165) 377,667 (10,212,420) (7,436,623)
Income taxes (benefit) 0 0 0 0
Net (loss) income (1,537,165) 377,667 (10,212,420) (7,436,623)
Preferred stock dividend (24,726) (53,048) (85,467) (244,516)
NET (LOSS) INCOME AVAILABLE TO COMMON STOCKHOLDERS $ (1,561,891) $ 324,619 $ (10,297,887) $ (7,681,139)
Net (loss) income per common share, basic and diluted (in Dollars per share) $ (0.08) $ 0.02 $ (0.55) $ (0.57)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 20,581,041 14,849,127 18,847,515 13,565,453
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2016 - USD ($)
Embedded Derivative Financial Instruments [Member]
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Embedded Derivative Financial Instruments [Member]
Series C Preferred Stock [Member]
Settlement of Series C Preferred Stock and Accrued Dividends [Member[
Series C Preferred Stock [Member]
Common Stock [Member]
Settlement of Series C Preferred Stock and Accrued Dividends [Member[
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Settlement of Series C Preferred Stock and Accrued Dividends [Member[
Series C Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2015                 $ 16,826 $ 29,314,399 $ (32,241,856) $ (2,910,631)
Balance (in Shares) at Dec. 31, 2015                 16,825,703     16,825,703
Sale of common stock                 $ 2,208 3,051,660   $ 3,053,868
Sale of common stock (in Shares)                 2,208,514     2,208,514
Common stock issued for services                 $ 1,335 2,469,715   $ 2,471,050
Common stock issued for services (in Shares)                 1,335,000      
Common stock issued upon conversion of preferred stock and accrued dividends     $ 53 $ 84,302 $ 84,355 $ 254 $ 380,746 $ 381,000        
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)     53,331     254,000            
Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares $ 97,897 $ 97,897                   97,897
Stock based compensation                 $ 259 2,981,931   2,982,190
Stock based compensation (in Shares)                 258,545      
Preferred Stock dividend                   (85,467)   (85,467)
Net loss                     (10,212,420) (10,212,420)
Balance at Sep. 30, 2016                 $ 20,935 $ 38,295,183 $ (42,454,276) $ (4,138,158)
Balance (in Shares) at Sep. 30, 2016                 20,935,093     20,935,093
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) - Series C Preferred Stock [Member] - Additional Paid-in Capital [Member]
Sep. 30, 2016
$ / shares
Preferred stock issued $ 1.50
Settlement of Series C Preferred Stock and Accrued Dividends [Member[  
Preferred stock issued $ 1.58
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (10,212,420) $ (7,436,623)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation 7,811 7,948
Amortization of debt discount 0 585,324
Change in derivative liabilities 807,087 (3,050,318)
Equity based compensation 5,453,240 6,907,423
Changes in operating assets and liabilities:    
Prepaid expenses (103,222) (8,141)
Accounts payable 202,534 (213,754)
Stock based payable 0 (226,305)
Deferred rent payable 417 2,713
Net cash used in operating activities (3,844,553) (3,431,733)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (12,095) (8,971)
Payment of long term deposit 0 (2,612)
Net cash used in investing activity (12,095) (11,583)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from sale of common stock 3,053,868 3,042,213
Proceeds from sale of Series C preferred stock 0 450,000
Proceeds from exercise of options 0 20,900
Proceeds from exercise of warrants 0 24,981
Net cash provided by financing activities 3,053,868 3,538,094
Net (decrease) increase in cash and cash equivalents (802,780) 94,778
Cash and cash equivalents, beginning of the period 953,234 239,781
Cash and cash equivalents, end of the period 150,454 334,559
Supplemental disclosures of cash flow information:    
Cash paid during the period for interest 0 1,298
Cash paid during the period for income taxes 0 0
Series C Preferred Stock [Member]    
Non-cash investing and financing activities:    
Common stock issued upon conversion of Series C Preferred Stock and accrued dividends $ 465,355 $ 1,654,811
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2016
Disclosure Text Block [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.

The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

The condensed balance sheet as of December 31, 2015 has been derived from audited financial statements.

Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 14, 2016.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS
 9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]
NOTE 2 –GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As of September 30, 2016, the Company had cash of $150,454 and working capital deficit (current liabilities in excess of current assets) of $3,098,462 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised approximately $450,000 in October 2016 through the sale of common stock and warrants (See Note 11). As of September 30, 2016, excluding the derivative and warrant liabilities, the Company's working capital deficit would have been $482,916. During the nine months ended September 30, 2016, the Company used net cash in operating activities of $3,844,553.  These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 2 months.

The Company's primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders' deficiencies at September 30, 2016 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.

Accordingly, the accompanying condensed financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed financial statements do not include any adjustment that might result from the outcome of this uncertainty.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.

At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).

Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514 and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively.

Net Earnings (Loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.

Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:

 
  
September 30,
2016
    
September 30,
2015
  
Series C convertible preferred stock
    
726,667
      
1,238,667
  
Options to purchase common stock
    
8,090,190
      
7,405,190
  
Warrants to purchase common stock
    
8,333,235
      
6,372,677
  
Totals
    
17,150,092
      
16,474,467
  

Stock Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested.

As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate.  Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.

Registration Rights

The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.

Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on April 29, 2016. On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.

Reclassification

Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 4 - PROPERTY AND EQUIPMENT
 9 Months Ended
Sep. 30, 2016
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Disclosure [Text Block]
NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows:

 
  
September 30,
2016
    
December 31,
2015
  
Computer equipment
  
$
80,544
    
$
68,449
  
Furniture and fixtures
    
10,117
      
10,117
  
Subtotal
    
90,661
      
78,566
  
Less accumulated depreciation
    
(67,969
)
    
(60,158
)
Property and equipment, net
  
$
22,692
    
$
18,408
  

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

Depreciation expense was $2,570 and $7,811 for the three and nine months ended September 30, 2016, respectively; and $2,607 and $7,948 for the three and nine months ended September 30, 2015, respectively.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 9 Months Ended
Sep. 30, 2016
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following:

 
  
September 30,
2016
    
December 31,
2015
  
Accrued accounting and legal
  
$
185,630
    
$
112,723
  
Accrued reimbursements
    
-
      
13,613
  
Accrued consulting
    
3,500
      
15,200
  
Accrued research and development expenses
    
177,577
      
34,179
  
Accrued office and other
    
7,190
      
31,482
  
Accrued payroll
    
35,835
      
-
  
Deferred rent
    
3,432
      
3,016
  
Accrued settlement related to arbitration
    
13,333
      
13,333
  
 
  
$
426,497
    
$
223,546
  

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK
 9 Months Ended
Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]  
Preferred Stock [Text Block]
NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK

On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.  The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:

●
incur additional indebtedness;
●
permit liens on assets;
●
repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;
●
pay cash dividends to our stockholders; and
●
engage in transactions with affiliates.

Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.

In the event that:

  (i)  
we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,
(ii)  
we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,
(iii)  
we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,
 (iv)  
we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,
(v)  
we are party to a change of control transaction,
(vi)  
we file for bankruptcy or a similar arrangement or are adjudicated insolvent,
(vii)  
we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,

The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity.

In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. 

As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301.

In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense.

During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock.

During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910.

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There was no established market for the Company’s common stock.  As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.

At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%.

In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

For the nine months ended September 30, 2016, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $97,897 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.23% to 0.59%, a dividend yield of 0%, and volatility of 141% to 150%.

Series C Preferred Stock issued and outstanding totaled 1,090 and 1,471 as of September30, 2016 and December 31, 2015, respectively.  As of September 30, 2016 and December 31, 2015, the Company has accrued $341,403 and $340,291 dividends payable on the Series C Preferred Stock.

Registration Rights Agreement

In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.

If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.

Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.

Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.

The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.  As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement as of December 31, 2014. At December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES
 9 Months Ended
Sep. 30, 2016
Disclosure Text Block [Abstract]  
Derivatives and Fair Value [Text Block]
NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES

At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively.

The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%.

At September 30, 2016, the Company marked to market the fair value of the reset provisions of the Series C Preferred Stock and warrants and determined fair values of $291,086 and $2,324,460, respectively. The Company recorded a gain(loss) from change in fair value of derivatives of $17,771 and $(807,087) for the three and nine months ended September 30, 2016. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 0.49 to 3.61 years, a risk free interest rate of 0.39% to 1.01%, a dividend yield of 0%, and volatility of 143.00% to 152.00%.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 8 - STOCKHOLDER EQUITY
 9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
NOTE 8 – STOCKHOLDER EQUITY

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of September 30, 2016 and December 31, 2015, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 shares of Series C Preferred Stock. As of September 30, 2016 and December 31, 2015, there were no outstanding shares of Series A and Series B preferred stock.

In February 2016, the Company issued 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends.

In May 2016, the Company issued an aggregate of 197,714 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends.

In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends.

As of September 30, 2016 and December 31, 2015, the Company has 1,090 and 1,471 Series C Preferred Stock issued and outstanding.

Common stock

The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of September 30, 2016 and December 31, 2015, the Company had 20,935,093 and 16,825,703 shares issued and outstanding, respectively.

During the nine months ended September 30, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share).

During the nine months ended September 30, 2016, the Company issued an aggregate of 545,000 shares of common stock  for services rendered totaling $1,051,850 ($1.93 average per share).

During the nine months ended September 30, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,208,514 shares of common stock and 1,254,550 warrants for aggregate proceeds of $3,053,868, net of $278,188 in expenses.

During the nine months ended September 30, 2016, the Company issued 175,000 shares of common stock as vested previously issued restricted stock units

During the nine months ended September 30, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement. 

The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter.  The final closing under the Private Placement occurred on April 29, 2016.  On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS
 9 Months Ended
Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]  
Shareholders' Equity and Share-based Payments [Text Block]
NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

Options

On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 11,686,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan.

During the nine months ended September 30, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers, directors and key consultants.

During the nine months ended September 30, 2016, the Company granted an aggregate of 873,545 stock grants to officers, employees and key consultants under the plan. See Note 8.

The following table presents information related to stock options at September 30, 2016:

Options Outstanding
  
Options Exercisable
  
       
Weighted
      
       
Average
  
Exercisable
  
Exercise
  
Number of
  
Remaining Life
  
Number of
  
Price
  
Options
  
In Years
  
Options
  
 
$
1.01-2.00
      
2,139,642
      
6.8
      
1,572,642
  
   
2.01-3.00
      
5,650,548
      
5.6
      
4,872,457
  
   
3.01-4.00
      
300,000
      
8.5
      
300,000
  
           
8,090,190
      
6.0
      
6,745,099
  

A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2016 is as follows:

 
              
Weighted-Average
        
 
        
Weighted-Average
    
Remaining
    
Aggregate
  
 
  
Shares
    
Exercise Price
    
Contractual Term
    
Intrinsic Value
  
Outstanding at January 1, 2016
    
7,780,190
    
$
2.30
      
6.4
    
$
-
  
Grants
    
750,000
      
1.80
      
10.0
      
-
  
Exercised
    
-
                          
Forfeiture/Canceled
    
(440,000
)
  
$
2.24
      
-
      
-
  
Outstanding at September 30, 2016
    
8,090,190
    
$
2.26
      
6.0
    
$
12,350
  
Exercisable at September 30, 2016
    
6,745,099
    
$
2.31
      
6.0
    
$
3,563
  

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.52 as of September 30, 2016, which would have been received by the option holders had those option holders exercised their options as of that date.

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from using the Company’s historical stock prices for 2016. Prior to 2016, the Company derived the volatility figure from an index of historical stock prices for comparable entities. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification.

The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. 

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

The Company estimated forfeitures related to option grants at a weighted average annual rate of  0% per year, as the Company does not yet have adequate historical data, for options granted during the nine months ended September 30, 2016 and 2015.

The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015:

 
September 30,
2016
 
September 30,
2015
 
Risk-free interest rate
 
 
1.08% - 1.69
%
 
 
1.19% - 2.37
%
Dividend yield
 
 
0
%
 
 
0
%
Stock price volatility
 
 
122.82
%
 
 
118.56% -130.30
%
Expected life
5 – 10 years
 
7-10 years
 
Weighted average grant date fair value
 
$
1.50
 
 
$
2.41
 

During the nine months ended September 30, 2016, the Company granted an aggregate of  685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan.  The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions:  dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84.

On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent.

The fair value of all options vesting during the three and nine months ended September 30, 2016 of $218,085 and $2,512,886, respectively, and during the three and nine months ended September 30, 2015 of $836,425 and $3,793,152, respectively, was charged to current period operations.  Unrecognized compensation expense of $406,988 at September 30, 2016 will be expensed in future periods.

Restricted Stock

The following table summarizes the restricted stock activity for the nine months ended September 30, 2016:

Restricted shares issued as of January 1, 2016
    
175,000
  
Granted
    
180,000
  
Vested
    
(175,000
)
Total restricted shares issued as of September 30, 2016
    
180,000
  
Vested restricted shares as of September 30, 2016
    
-
  
Unvested restricted shares as of September 30, 2016
    
180,000
  

On September 7, 2016, the Company granted 180,000 restricted stock units (“RSU”) to a consultant vesting monthly over one year beginning October 7, 2016.

Stock based compensation expense related to restricted stock grants was $70,753 and $124,139 for the three months ended September 30, 2016, respectively; and $100,492 and $238,122 for the three and nine months ended September 30, 2015,  respectively. As of September 30, 2016, the stock-based compensation relating to restricted stock of $202,847 remain unamortized and is expected to be amortized over the remaining period of approximately 1 year.    

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016: 

Exercise
    
Number
  
Expiration
Price
    
Outstanding
  
Date
$
0.001
      
383,320
  
January 2020
$
1.50
      
4,173,017
  
February 2018 to May 2020
$
1.84
      
35,076
  
January 2020
$
1.95
      
1,689,026
  
October 2018 to September 2019
$
2.00
      
100,000
  
August 2018
$
2.02
      
30,755
  
January 2020
$
2.10
      
38,572
  
June 2019
$
2.50
      
100,000
  
August 2018
$
2.75
      
228,720
  
August 2019 to September 2019
$
3.67
      
214,193
  
December 2018 to January 2019
$
3.75
      
1,340,556
  
April 2019 to March 2020
         
8,333,235
  
 

On February 9, 2016, the Company issued 25,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services.

On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services.

On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 18,040 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services.

On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 17,996 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services.

On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company’s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services.

On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company’s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company’s common stock.

On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company’s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company’s common stock.

On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company’s common stock.

Stock based compensation related to warrants issued for services was $641 and $56,930 for the three and nine months ended September 30, 2016, respectively; and $44,464 for the three and nine months ended September 30, 2015.

A summary of the warrant activity for the nine months ended September 30, 2016 is as follows:

 
              
Weighted-Average
        
 
        
Weighted-Average
    
Remaining
    
Aggregate
  
 
  
Shares
    
Exercise Price
    
Contractual Term
    
Intrinsic Value
  
Outstanding at January 1, 2016
    
7,078,685
    
$
2.02
      
3.0
      
497,933
  
Grants
    
1,254,550
      
1.90
      
2.5
      
-
  
Exercised
    
-
                          
Canceled
    
-
                          
Outstanding at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
 
                                
Vested and expected to vest at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
Exercisable at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.52 as of September 30, 2016, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 10 - FAIR VALUE MEASUREMENT
 9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
NOTE 10 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of September 30, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1 or 2 disclosures.

The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company.

As of September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.

The derivative and warrant liability as of September 30, 2016, in the amount of $291,086 and $2,324,460, respectively, has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2016:

 
  
Warrant
Liability
    
Derivative
  
Balance, December 31, 2015
  
$
1,621,199
    
$
285,157
  
Total (gains) losses
                
Transfers out due to conversion of Series C Preferred Stock
    
-
      
(97,897
)
Mark to market to September 30, 2016
    
703,261
      
103,826
  
Balance, September 30, 2016
  
$
2,324,460
    
$
291,086
  
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016
  
$
(703,261
)
  
$
(103,826
)

Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 11 - SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
NOTE 11 – SUBSEQUENT EVENTS

On October 16, 2016, the Company issued 15,000 shares of its common stock to a consultant for services rendered valued at $22,800.

On October 28, 2016, the Company entered into securities purchase agreements with investors, pursuant to which the Company received from subscriptions for the purchase of 346,567 shares of the Company’s common stock and warrants to purchase 173,284 shares of our common stock at $1.50, expiring three years from issuance, for aggregate net cash proceeds of $450,477, after financing costs of $69,373.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies, by Policy (Policies)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]
Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]
Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges.

At September 30, 2016 and December 31, 2015, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 7).
Research and Development Expense, Policy [Policy Text Block]
Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $560,514 and $2,139,671 for the three and nine months ended September 30, 2016; and $354,471 and $1,146,113 for the three and nine months ended September 30, 2015, respectively.
Earnings Per Share, Policy [Policy Text Block]
Net Earnings (Loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted income (loss) per share as of September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.

Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:

 
  
September 30,
2016
    
September 30,
2015
  
Series C convertible preferred stock
    
726,667
      
1,238,667
  
Options to purchase common stock
    
8,090,190
      
7,405,190
  
Warrants to purchase common stock
    
8,333,235
      
6,372,677
  
Totals
    
17,150,092
      
16,474,467
  
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

As of September 30, 2016, the Company had 8,090,190 options outstanding to purchase shares of common stock, of which 6,745,099 were vested.

As of December 31, 2015, the Company had 7,780,190 options outstanding to purchase shares of common stock, of which 5,613,501 were vested.
Income Tax, Policy [Policy Text Block]
Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate.  Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Registration Rights Policy [Policy Text Block]
Registration Rights

The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.

Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “Private Placement”).  In connection with the Private Placement, the Company also entered into a registration rights agreements with the investors, pursuant to which the Company agreed to provide certain registration rights with respect to the common stock and warrants issued under the Private Placement.  The registration rights agreements require the Company to file a registration statement within 45 calendar days upon the final closing under the Private Placement and to be effective 120 calendar days thereafter. The final closing under the Private Placement occurred on April 29, 2016. On August 2, 2016, the Company filed Form S-1 registration statement which became effective August 9, 2016. The Company has estimated the liability under the registration rights agreement at $-0- as of September 30, 2016.
Reclassification, Policy [Policy Text Block]
Reclassification

Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]
Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.  Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:

 
  
September 30,
2016
    
September 30,
2015
  
Series C convertible preferred stock
    
726,667
      
1,238,667
  
Options to purchase common stock
    
8,090,190
      
7,405,190
  
Warrants to purchase common stock
    
8,333,235
      
6,372,677
  
Totals
    
17,150,092
      
16,474,467
  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 4 - PROPERTY AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2016
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment [Table Text Block] Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows:

 
  
September 30,
2016
    
December 31,
2015
  
Computer equipment
  
$
80,544
    
$
68,449
  
Furniture and fixtures
    
10,117
      
10,117
  
Subtotal
    
90,661
      
78,566
  
Less accumulated depreciation
    
(67,969
)
    
(60,158
)
Property and equipment, net
  
$
22,692
    
$
18,408
  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
 9 Months Ended
Sep. 30, 2016
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 consist of the following:

 
  
September 30,
2016
    
December 31,
2015
  
Accrued accounting and legal
  
$
185,630
    
$
112,723
  
Accrued reimbursements
    
-
      
13,613
  
Accrued consulting
    
3,500
      
15,200
  
Accrued research and development expenses
    
177,577
      
34,179
  
Accrued office and other
    
7,190
      
31,482
  
Accrued payroll
    
35,835
      
-
  
Deferred rent
    
3,432
      
3,016
  
Accrued settlement related to arbitration
    
13,333
      
13,333
  
 
  
$
426,497
    
$
223,546
  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)
 9 Months Ended
Sep. 30, 2016
Disclosure Text Block Supplement [Abstract]  
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] The following table presents information related to stock options at September 30, 2016:

Options Outstanding
  
Options Exercisable
  
       
Weighted
      
       
Average
  
Exercisable
  
Exercise
  
Number of
  
Remaining Life
  
Number of
  
Price
  
Options
  
In Years
  
Options
  
 
$
1.01-2.00
      
2,139,642
      
6.8
      
1,572,642
  
   
2.01-3.00
      
5,650,548
      
5.6
      
4,872,457
  
   
3.01-4.00
      
300,000
      
8.5
      
300,000
  
           
8,090,190
      
6.0
      
6,745,099
  
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2016 is as follows:

 
              
Weighted-Average
        
 
        
Weighted-Average
    
Remaining
    
Aggregate
  
 
  
Shares
    
Exercise Price
    
Contractual Term
    
Intrinsic Value
  
Outstanding at January 1, 2016
    
7,780,190
    
$
2.30
      
6.4
    
$
-
  
Grants
    
750,000
      
1.80
      
10.0
      
-
  
Exercised
    
-
                          
Forfeiture/Canceled
    
(440,000
)
  
$
2.24
      
-
      
-
  
Outstanding at September 30, 2016
    
8,090,190
    
$
2.26
      
6.0
    
$
12,350
  
Exercisable at September 30, 2016
    
6,745,099
    
$
2.31
      
6.0
    
$
3,563
  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] The following assumptions were used in determining the fair value of employee and vesting non-employee options during the nine months ended September 30, 2016 and 2015:

 
September 30,
2016
 
September 30,
2015
 
Risk-free interest rate
 
 
1.08% - 1.69
%
 
 
1.19% - 2.37
%
Dividend yield
 
 
0
%
 
 
0
%
Stock price volatility
 
 
122.82
%
 
 
118.56% -130.30
%
Expected life
5 – 10 years
 
7-10 years
 
Weighted average grant date fair value
 
$
1.50
 
 
$
2.41
 
Nonvested Restricted Stock Shares Activity [Table Text Block] The following table summarizes the restricted stock activity for the nine months ended September 30, 2016:

Restricted shares issued as of January 1, 2016
    
175,000
  
Granted
    
180,000
  
Vested
    
(175,000
)
Total restricted shares issued as of September 30, 2016
    
180,000
  
Vested restricted shares as of September 30, 2016
    
-
  
Unvested restricted shares as of September 30, 2016
    
180,000
  
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2016:

Exercise
    
Number
  
Expiration
Price
    
Outstanding
  
Date
$
0.001
      
383,320
  
January 2020
$
1.50
      
4,173,017
  
February 2018 to May 2020
$
1.84
      
35,076
  
January 2020
$
1.95
      
1,689,026
  
October 2018 to September 2019
$
2.00
      
100,000
  
August 2018
$
2.02
      
30,755
  
January 2020
$
2.10
      
38,572
  
June 2019
$
2.50
      
100,000
  
August 2018
$
2.75
      
228,720
  
August 2019 to September 2019
$
3.67
      
214,193
  
December 2018 to January 2019
$
3.75
      
1,340,556
  
April 2019 to March 2020
         
8,333,235
  
 
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] A summary of the warrant activity for the nine months ended September 30, 2016 is as follows:

 
              
Weighted-Average
        
 
        
Weighted-Average
    
Remaining
    
Aggregate
  
 
  
Shares
    
Exercise Price
    
Contractual Term
    
Intrinsic Value
  
Outstanding at January 1, 2016
    
7,078,685
    
$
2.02
      
3.0
      
497,933
  
Grants
    
1,254,550
      
1.90
      
2.5
      
-
  
Exercised
    
-
                          
Canceled
    
-
                          
Outstanding at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
 
                                
Vested and expected to vest at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
Exercisable at September 30, 2016
    
8,333,235
    
$
2.00
      
2.3
    
$
665,723
  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 10 - FAIR VALUE MEASUREMENT (Tables)
 9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of September 30, 2016:

 
  
Warrant
Liability
    
Derivative
  
Balance, December 31, 2015
  
$
1,621,199
    
$
285,157
  
Total (gains) losses
                
Transfers out due to conversion of Series C Preferred Stock
    
-
      
(97,897
)
Mark to market to September 30, 2016
    
703,261
      
103,826
  
Balance, September 30, 2016
  
$
2,324,460
    
$
291,086
  
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016
  
$
(703,261
)
  
$
(103,826
)
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)
 1 Months Ended 9 Months Ended
Oct. 31, 2016
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]          
Cash and Cash Equivalents, at Carrying Value   $ 150,454 $ 334,559 $ 953,234 $ 239,781
Working Capital (Deficit)   (3,098,462)      
Net Cash Provided by (Used in) Operating Activities   (3,844,553) $ (3,431,733)    
Subsequent Event [Member]          
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]          
Proceeds from Issuance of Private Placement $ 450,000        
Working Captial, Excluding Derivative and Warrant Liabilties [Member]          
NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) [Line Items]          
Working Capital (Deficit)   $ 482,916      
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]            
Research and Development Expense $ 560,514 $ 354,471 $ 2,139,671 $ 1,146,113    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) 8,090,190   8,090,190   7,780,190  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares) 6,745,099   6,745,099      
Registration Payment Arrangement, Accrual Carrying Value $ 0   $ 0   $ 0 $ 55,620
Employee Stock Option [Member]            
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) 8,090,190   8,090,190   7,780,190  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares) 6,745,099   6,745,099   5,613,501  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 17,150,092 16,474,467
Employee Stock Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 8,090,190 7,405,190
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 8,333,235 6,372,677
Series C Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 726,667 1,238,667
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]        
Depreciation $ 2,570 $ 2,607 $ 7,811 $ 7,948
Minimum [Member]        
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]        
Property, Plant and Equipment, Useful Life     3 years  
Maximum [Member]        
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]        
Property, Plant and Equipment, Useful Life     5 years  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 90,661 $ 78,566
Less accumulated depreciation (67,969) (60,158)
Property and equipment, net 22,692 18,408
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 80,544 68,449
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 10,117 $ 10,117
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Schedule of Accounts Payable and Accrued Liabilities [Abstract]    
Accrued accounting and legal $ 185,630 $ 112,723
Accrued reimbursements 0 13,613
Accrued consulting 3,500 15,200
Accrued research and development expenses 177,577 34,179
Accrued office and other 7,190 31,482
Accrued payroll 35,835 0
Deferred rent 3,432 3,016
Accrued settlement related to arbitration 13,333 13,333
$ 426,497 $ 223,546
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Feb. 06, 2013
Jan. 09, 2013
Jun. 30, 2016
May 31, 2016
Feb. 29, 2016
Mar. 31, 2015
Jul. 31, 2013
Sep. 30, 2016
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2013
Dec. 31, 2015
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Class of Warrant or Rights, Granted (in Shares)               1,254,550        
Class of Warrant or Right, Outstanding (in Shares)               8,333,235       7,078,685
Temporary Equity, Amortization Period                   1 year    
Stock Issued During Period, Shares, New Issues (in Shares)               2,208,514        
Embedded Derivative, Fair Value of Embedded Derivative Liability           $ 1,242,590   $ 291,086       $ 285,157
Fair Value Assumptions, Expected Term               2 years        
Fair Value Assumptions, Expected Dividend Rate           0.00%   0.00%        
Fair Value Assumptions, Expected Volatility Rate           141.00%            
Conversion of Stock, Shares Issued (in Shares)         54,859              
Conversion of Stock, Shares Converted (in Shares)     54,759 197,714                
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity               $ 97,897        
Dividends Payable, Current               341,403       340,291
Registration Payment Arrangement, Term                 the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.      
Registration Payment Arrangement, Accrual Carrying Value               0 $ 55,620     0
Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Temporary Equity, Shares Authorized (in Shares)   4,200                    
Preferred Stock, Dividend Rate, Percentage   9.00%                    
Temporary Equity, Par Value   $ 1,000                    
Preferred Stock, Dividend Payment Terms   payable quarterly                    
Preferred Stock, Voting Rights   The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.                    
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description   The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:●incur additional indebtedness;●permit liens on assets;●repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;●pay cash dividends to our stockholders; and●engage in transactions with affiliates.                    
Convertible Preferred Stock, Terms of Conversion   Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:(i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v) we are party to a change of control transaction,(vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.                    
Temporary Equity, Redemption Price Per Share (in Dollars per share)   $ 1.50                    
Class of Warrant or Rights, Granted (in Shares)   1,330,627                    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 2.61                    
Warrants, Term of Warrants   5 years                    
Warrant, Description of Warrant   after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.                    
Temporary Equity, Liquidation Preference               $ 1,090,000   $ 2,781,000 $ 2,781,000 $ 1,471,000
Stock Issued During Period, Shares, New Issues (in Shares)             2,181          
Proceeds from Issuance of Redeemable Preferred Stock             $ 1,814,910          
Conversion of Stock, Shares Converted (in Shares)     70 236 75              
Temporary Equity, Shares Outstanding (in Shares)               1,090       1,471
Series C Preferred Stock [Member] | Full-Ratchet Anti-Dilution Protection Provision [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 1.50                    
Class of Warrant or Right, Outstanding (in Shares)   2,315,301                    
Bridge Loan [Member] | Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Debt Conversion, Converted Instrument, Shares Issued (in Shares) 600                      
Embedded Beneficial Conversion Feature [Member] | Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Adjustments to Additional Paid in Capital, Other                     1,303,671  
Temporary Equity, Liquidation Preference                   1,303,671 1,303,671  
Warrant [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Embedded Derivative, Fair Value of Embedded Derivative Liability           $ 4,097,444            
Warrant [Member] | Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Adjustments to Additional Paid in Capital, Warrant Issued                     1,064,739  
Temporary Equity, Liquidation Preference                   1,064,739 1,064,739  
Issuance Costs [Member] | Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Temporary Equity, Liquidation Preference                   $ 412,590 $ 412,590  
Minimum [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Fair Value Assumptions, Expected Term           2 years 284 days            
Fair Value Assumptions, Risk Free Interest Rate           0.56%            
Fair Value Assumptions, Expected Volatility Rate               141.00%        
Minimum [Member] | Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Fair Value Assumptions, Risk Free Interest Rate               0.23%        
Maximum [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Fair Value Assumptions, Expected Term           3 years 6 months            
Fair Value Assumptions, Risk Free Interest Rate           0.89%            
Fair Value Assumptions, Expected Volatility Rate               150.00%        
Maximum [Member] | Series C Preferred Stock [Member]                        
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]                        
Fair Value Assumptions, Risk Free Interest Rate               0.59%        
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Mar. 31, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]            
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars) $ 291,086   $ 1,242,590 $ 291,086   $ 285,157
Derivative Liability, Current (in Dollars) 2,324,460   $ 4,097,444 $ 2,324,460   $ 1,621,199
Fair Value Assumptions, Expected Dividend Rate     0.00% 0.00%    
Fair Value Assumptions, Expected Volatility Rate     141.00%      
Derivative, Gain (Loss) on Derivative, Net (in Dollars) 17,771 $ 2,851,755   $ (807,087) $ 3,050,318  
Fair Value Assumptions, Expected Term       2 years    
Embedded Derivative Financial Instruments [Member]            
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]            
Derivative Liability, Current (in Dollars) $ 291,086     $ 291,086    
Fair Value Assumptions, Expected Dividend Rate       0.00%    
Derivative, Gain (Loss) on Derivative, Net (in Dollars)       $ (103,826)    
Minimum [Member]            
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]            
Fair Value Assumptions, Risk Free Interest Rate     0.56%      
Fair Value Assumptions, Expected Volatility Rate       141.00%    
Fair Value Assumptions, Expected Term     2 years 284 days      
Minimum [Member] | Embedded Derivative Financial Instruments [Member]            
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]            
Fair Value Assumptions, Risk Free Interest Rate       0.39%    
Fair Value Assumptions, Expected Volatility Rate       143.00%    
Fair Value Assumptions, Expected Term       178 days    
Maximum [Member]            
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]            
Fair Value Assumptions, Risk Free Interest Rate     0.89%      
Fair Value Assumptions, Expected Volatility Rate       150.00%    
Fair Value Assumptions, Expected Term     3 years 6 months      
Maximum [Member] | Embedded Derivative Financial Instruments [Member]            
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]            
Fair Value Assumptions, Risk Free Interest Rate       1.01%    
Fair Value Assumptions, Expected Volatility Rate       152.00%    
Fair Value Assumptions, Expected Term       3 years 222 days    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 8 - STOCKHOLDER EQUITY (Details) - USD ($)
 1 Months Ended 6 Months Ended 9 Months Ended
Oct. 23, 2015
Jan. 09, 2013
Jun. 30, 2016
May 31, 2016
Feb. 29, 2016
Jul. 31, 2013
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]                    
Preferred Stock, Shares Authorized             1,000,000   1,000,000  
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)             $ 0.001   $ 0.001  
Conversion of Stock, Shares Issued         54,859          
Conversion of Stock, Shares Converted     54,759 197,714            
Common Stock, Shares Authorized             50,000,000   50,000,000  
Common Stock, Par or Stated Value Per Share (in Dollars per share)             $ 0.001   $ 0.001  
Common Stock, Shares, Issued             20,935,093   16,825,703  
Common Stock, Shares, Outstanding             20,935,093   16,825,703  
Stock Issued During Period, Shares, Share-based Compensation, Gross             83,545      
Stock Issued During Period, Value, Issued for Services (in Dollars)             $ 2,471,050      
Stock Issued During Period, Shares, New Issues             2,208,514      
Class of Warrant or Rights, Granted             1,254,550      
Proceeds from Issuance or Sale of Equity (in Dollars)             $ 3,053,868      
Payments of Stock Issuance Costs (in Dollars)             $ 278,188      
Stock Issued During Period, Shares, Other             175,000      
Stock Issued During Period, Value, Stock Options Exercised (in Dollars)             $ 100,000      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate             0.00% 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate             122.82%      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate             1.08%      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term             5 years      
Share Price (in Dollars per share)             $ 1.84      
Private Placement, Unit Description each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock                  
Registration Rights Agreement, Description The registration rights agreements require the Company to file a registration statement within 45 calendar days of the final closing under the Private Placement and to be effective 120 calendar days thereafter.                  
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)             $ 0   $ 0 $ 55,620
2012 Equity Incentive Plan [Member]                    
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]                    
Stock Issued During Period, Shares, Share-based Compensation, Gross             790,000      
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)             $ 1,419,200      
Shares Issued, Price Per Share (in Dollars per share)             $ 1.80      
Series A Preferred Stock [Member]                    
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]                    
Preferred Stock, Shares Authorized             200   200  
Series B Preferred Stock [Member]                    
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]                    
Preferred Stock, Shares Authorized             600   600  
Series C Preferred Stock [Member]                    
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]                    
Preferred Stock, Shares Authorized             4,200   4,200  
Conversion of Stock, Shares Converted     70 236 75          
Temporary Equity, Shares Issued             1,090   1,471  
Temporary Equity, Shares Outstanding             1,090   1,471  
Stock Issued During Period, Shares, New Issues           2,181        
Class of Warrant or Rights, Granted   1,330,627                
Services Provided [Member]                    
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]                    
Shares Issued, Price Per Share (in Dollars per share)             $ 1.93      
Stock Issued During Period, Shares, Issued for Services             545,000      
Stock Issued During Period, Value, Issued for Services (in Dollars)             $ 1,051,850      
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 19, 2016
Sep. 07, 2016
Aug. 30, 2016
Aug. 24, 2016
Jun. 01, 2016
Apr. 29, 2016
Apr. 19, 2016
Apr. 01, 2016
Mar. 09, 2016
Feb. 09, 2016
Oct. 19, 2012
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                             750,000  
Share Price (in Dollars per share)                       $ 1.84 $ 1.84   $ 1.84  
Stock Issued During Period, Shares, Share-based Compensation, Gross                             83,545  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                             0.00% 0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                             122.82%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                             1.08%  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)                             $ 1.80  
Share-based Compensation (in Dollars)                             $ 5,453,240 $ 6,907,423
Class of Warrant or Rights, Granted                             1,254,550  
Warrant [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation (in Dollars)                         $ 641   $ 56,930 9
Warrant [Member] | Private Placement [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share Price (in Dollars per share)                       1.52 $ 1.52   $ 1.52  
Services Provided [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation (in Dollars)                           $ 44,464    
Employee Stock Option [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       65,000                        
Share Price (in Dollars per share)                       $ 1.84 $ 1.84   $ 1.84  
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period       10 years                        
Stock Issued During Period, Shares, Share-based Compensation, Gross                       83,545        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period                       100,000        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                       0.00%        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                       122.82%        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                       1.08%        
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term                       5 years        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)       $ 1.33                        
Restricted Stock Units (RSUs) [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period   1 year                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period   180,000                            
Restricted Stock [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted                             180,000  
Share-based Compensation (in Dollars)                         $ 70,753 100,492 $ 124,139 238,122
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)                       $ 202,847 $ 202,847   $ 202,847  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition                             1 year  
2012 Equity Incentive Plan [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Stock Issued During Period, Shares, Share-based Compensation, Gross                             790,000  
2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                     11,686,123          
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award                     the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.          
Common Stock, Capital Shares Reserved for Future Issuance                     227,388          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                             750,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period                             100,000  
Share Price (in Dollars per share)                       $ 1.52 $ 1.52   $ 1.52  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate                             0.00%  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercise Price (in Dollars per share)                             $ 1.84  
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                             10 years  
Share-based Compensation (in Dollars)                         $ 218,085 $ 836,425 $ 2,512,886 $ 3,793,152
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)                       $ 406,988 $ 406,988   $ 406,988  
2012 Equity Incentive Plan [Member] | Employee Stock Option [Member] | Officers, Directors and Key Consultants [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted                             873,545  
Warrants at $1.95 [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                       $ 1.95 $ 1.95   $ 1.95  
Warrants at $1.95 [Member] | Private Placement [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Rights, Granted           567,866 84,980 100,327 100,000 25,000            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)           $ 1.95 $ 1.95 $ 1.95 $ 1.95 $ 1.95            
Warrant, Expriation Date           Apr. 29, 2019 Apr. 19, 2019 Apr. 01, 2019 Mar. 09, 2019              
Warrants at $1.95 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Rights, Granted             17,996 18,040                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)             $ 1.50 $ 1.50                
Warrant, Expriation Date             Apr. 19, 2019 Apr. 01, 2019   Feb. 09, 2019            
Warrants at $1.95 [Member] | Warrant [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Rights, Granted 35,000   152,513                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) $ 1.95   $ 1.95                          
Warrants at $1.50 [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                       1.50 1.50   1.50  
Warrants at $1.50 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Rights, Granted           96,256     12,000 6,000            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)           $ 1.50     $ 1.50 $ 1.50            
Warrant, Expriation Date                 Mar. 09, 2019 Feb. 09, 2019            
Warrants at $2.10 [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                       $ 2.10 $ 2.10   $ 2.10  
Warrants at $2.10 [Member] | Warrant [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Class of Warrant or Rights, Granted         38,572                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)         $ 2.10                      
Warrant, Expriation Date         Jun. 01, 2019                      
Share-based Compensation Award, Tranche One [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares       12,500                        
Share-based Compensation Award, Tranche Two [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares       37,500                        
Share-based Compensation Award, Tranche Three [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares       15,000                        
Maximum [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                               130.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                             1.69% 2.37%
Maximum [Member] | 2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                     10 years          
Maximum [Member] | Warrants at $1.50 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Warrant, Expriation Date           Apr. 29, 2019                    
Minimum [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate                               118.56%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate                             1.08% 1.19%
Minimum [Member] | Warrants at $1.50 [Member] | Warrants Issued to Placement Agents [Member] | Private Placement [Member]                                
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]                                
Warrant, Expriation Date           Oct. 23, 2018                    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]    
Options Outstanding, Number of Options 8,090,190 7,780,190
Options Outstanding, Weighted Average Remaining Life 6 years 6 years 146 days
Options Exercisable, Number of Options 6,745,099  
Options at $1.01-$2.00 [Member]    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]    
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share) $ 1.01  
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share) $ 2.00  
Options Outstanding, Number of Options 2,139,642  
Options Outstanding, Weighted Average Remaining Life 6 years 292 days  
Options Exercisable, Number of Options 1,572,642  
Options at $2.01-$3.00 [Member]    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]    
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share) $ 2.01  
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share) $ 3.00  
Options Outstanding, Number of Options 5,650,548  
Options Outstanding, Weighted Average Remaining Life 5 years 219 days  
Options Exercisable, Number of Options 4,872,457  
Options at $3.01-$4.00 [Member]    
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]    
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share) $ 3.01  
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share) $ 4.00  
Options Outstanding, Number of Options 300,000  
Options Outstanding, Weighted Average Remaining Life 8 years 6 months  
Options Exercisable, Number of Options 300,000  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]    
Options Outstanding, Shares 8,090,190 7,780,190
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share) $ 2.26 $ 2.30
Options Outstanding, Weighted-Average Remaining Contractual Term 6 years 6 years 146 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars) $ 12,350 $ 0
Exercisable at September 30, 2016 6,745,099  
Exercisable at September 30, 2016 (in Dollars per share) $ 2.31  
Exercisable at September 30, 2016 6 years  
Exercisable at September 30, 2016 (in Dollars) $ 3,563  
Grants 750,000  
Grants (in Dollars per share) $ 1.80  
Grants 10 years  
Exercised 0  
Forfeiture/Canceled (440,000)  
Forfeiture/Canceled (in Dollars per share) $ 2.24  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]    
Risk-free interest rate 1.08%  
Dividend yield 0.00% 0.00%
Stock price volatility 122.82%  
Expected life 5 years  
Weighted average grant date fair value (in Dollars per share) $ 1.50 $ 2.41
Minimum [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]    
Risk-free interest rate 1.08% 1.19%
Stock price volatility   118.56%
Expected life 5 years 7 years
Maximum [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]    
Risk-free interest rate 1.69% 2.37%
Stock price volatility   130.30%
Expected life 10 years 10 years
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - Restricted Stock [Member]
 9 Months Ended
Sep. 30, 2016
shares
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]  
Restricted shares issued as of January 1, 2016 175,000
Granted 180,000
Vested (175,000)
Total restricted shares issued as of September 30, 2016 180,000
Vested restricted shares as of September 30, 2016 0
Unvested restricted shares as of September 30, 2016 180,000
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares
 9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Number of Warrants Outstanding 8,333,235 7,078,685
Warrants at $0.001 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 0.001  
Number of Warrants Outstanding 383,320  
Expiration Date, Warrants January 2020  
Warrants at $1.50 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 1.50  
Number of Warrants Outstanding 4,173,017  
Expiration Date, Warrants February 2018 to May 2020  
Warrants at $1.84 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 1.84  
Number of Warrants Outstanding 35,076  
Expiration Date, Warrants January 2020  
Warrants at $1.95 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 1.95  
Number of Warrants Outstanding 1,689,026  
Expiration Date, Warrants October 2018 to September 2019  
Warrants at $2.00 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 2.00  
Number of Warrants Outstanding 100,000  
Expiration Date, Warrants August 2018  
Warrants at $2.02 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 2.02  
Number of Warrants Outstanding 30,755  
Expiration Date, Warrants January 2020  
Warrants at $2.10 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 2.10  
Number of Warrants Outstanding 38,572  
Expiration Date, Warrants June 2019  
Warrants at $2.50 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 2.50  
Number of Warrants Outstanding 100,000  
Expiration Date, Warrants August 2018  
Warrants at $2.75 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 2.75  
Number of Warrants Outstanding 228,720  
Expiration Date, Warrants August 2019 to September 2019  
Warrants at $3.67 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 3.67  
Number of Warrants Outstanding 214,193  
Expiration Date, Warrants December 2018 to January 2019  
Warrants at $3.75 [Member]    
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]    
Exercise Price, Warrants (in Dollars per share) $ 3.75  
Number of Warrants Outstanding 1,340,556  
Expiration Date, Warrants April 2019 to March 2020  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]    
Warrants Outstanding, Shares 8,333,235 7,078,685
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share) $ 2.00 $ 2.02
Warrants Outstanding, Weighted-Average Remaining Contractual Term 2 years 109 days 3 years
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars) $ 665,723 $ 497,933
Vested and expected to vest at September 30, 2016 8,333,235  
Vested and expected to vest at September 30, 2016 (in Dollars per share) $ 2.00  
Vested and expected to vest at September 30, 2016 2 years 109 days  
Vested and expected to vest at September 30, 2016 (in Dollars) $ 665,723  
Exercisable at September 30, 2016 8,333,235  
Exercisable at September 30, 2016 (in Dollars per share) $ 2.00  
Exercisable at September 30, 2016 2 years 109 days  
Exercisable at September 30, 2016 (in Dollars) $ 665,723  
Grants 1,254,550  
Grants (in Dollars per share) $ 1.90  
Grants 2 years 6 months  
Exercised 0  
Canceled 0  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 10 - FAIR VALUE MEASUREMENT (Details) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Mar. 31, 2015
Fair Value Disclosures [Abstract]      
Embedded Derivative, Fair Value of Embedded Derivative Liability $ 291,086 $ 285,157 $ 1,242,590
Derivative Liability, Current $ 2,324,460 $ 1,621,199 $ 4,097,444
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Total (gains) losses        
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016 $ 17,771 $ 2,851,755 $ (807,087) $ 3,050,318
Warrant [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Balance, December 31, 2015 1,621,199   1,621,199  
Total (gains) losses        
Transfers out due to conversion of Series C Preferred Stock     0  
Mark to market to September 30, 2016     703,261  
Balance, September 30, 2016     2,324,460  
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016     (703,261)  
Embedded Derivative Financial Instruments [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Balance, December 31, 2015 $ 285,157   285,157  
Total (gains) losses        
Transfers out due to conversion of Series C Preferred Stock     (97,897)  
Mark to market to September 30, 2016     103,826  
Balance, September 30, 2016     291,086  
Loss on change in warrant and derivative liabilities for the nine months ended September 30, 2016     $ (103,826)  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTE 11 - SUBSEQUENT EVENTS (Details) - USD ($)
 9 Months Ended
Oct. 28, 2016
Oct. 16, 2016
Sep. 30, 2016
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]      
Stock Issued During Period, Value, Issued for Services     $ 2,471,050
Stock Issued During Period, Shares, New Issues     2,208,514
Class of Warrant or Rights, Granted     1,254,550
Proceeds from Issuance or Sale of Equity     $ 3,053,868
Payments of Stock Issuance Costs     $ 278,188
Subsequent Event [Member]      
NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]      
Stock Issued During Period, Shares, Issued for Services   15,000  
Stock Issued During Period, Value, Issued for Services   $ 22,800  
Stock Issued During Period, Shares, New Issues 346,567    
Class of Warrant or Rights, Granted 173,284    
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.50    
Warrants, Term of Warrants 3 years    
Proceeds from Issuance or Sale of Equity $ 450,477    
Payments of Stock Issuance Costs $ 69,373    
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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g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end XML 55 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 177 231 1 false 47 0 false 4 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://BIOS/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONDENSED BALANCE SHEETS Sheet http://BIOS/role/ConsolidatedBalanceSheet CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONDENSED BALANCE SHEETS (Parentheticals) Sheet http://BIOS/role/ConsolidatedBalanceSheet_Parentheticals CONDENSED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONDENSED STATEMENTS OF OPERATIONS (unaudited) Sheet http://BIOS/role/ConsolidatedIncomeStatement CONDENSED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 004 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://BIOS/role/ShareholdersEquityType2or3 CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) Sheet http://BIOS/role/ShareholdersEquityType2or3_Parentheticals CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) Statements 6 false false R7.htm 006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://BIOS/role/ConsolidatedCashFlow CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Statements 7 false false R8.htm 007 - Disclosure - NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://BIOS/role/NOTE1NATUREOFOPERATIONSANDBASISOFPRESENTATION NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 008 - Disclosure - NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS Sheet http://BIOS/role/NOTE2GOINGCONCERNANDMANAGEMENTSLIQUIDITYPLANS NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS Notes 9 false false R10.htm 009 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://BIOS/role/NOTE3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 010 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT Sheet http://BIOS/role/NOTE4PROPERTYANDEQUIPMENT NOTE 4 - PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 011 - Disclosure - NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://BIOS/role/NOTE5ACCOUNTSPAYABLEANDACCRUEDEXPENSES NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 12 false false R13.htm 012 - Disclosure - NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK Sheet http://BIOS/role/NOTE6SERIESC9CONVERTIBLEPREFERREDSTOCK NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK Notes 13 false false R14.htm 013 - Disclosure - NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES Sheet http://BIOS/role/NOTE7WARRANTANDDERIVATIVELIABILITIES NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES Notes 14 false false R15.htm 014 - Disclosure - NOTE 8 - STOCKHOLDER EQUITY Sheet http://BIOS/role/NOTE8STOCKHOLDEREQUITY NOTE 8 - STOCKHOLDER EQUITY Notes 15 false false R16.htm 015 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Sheet http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTS NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Notes 16 false false R17.htm 016 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT Sheet http://BIOS/role/NOTE10FAIRVALUEMEASUREMENT NOTE 10 - FAIR VALUE MEASUREMENT Notes 17 false false R18.htm 017 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS Sheet http://BIOS/role/NOTE11SUBSEQUENTEVENTS NOTE 11 - SUBSEQUENT EVENTS Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://BIOS/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 19 false false R20.htm 019 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://BIOS/role/NOTE3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://BIOS/role/NOTE3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 20 false false R21.htm 020 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT (Tables) Sheet http://BIOS/role/NOTE4PROPERTYANDEQUIPMENTTables NOTE 4 - PROPERTY AND EQUIPMENT (Tables) Tables http://BIOS/role/NOTE4PROPERTYANDEQUIPMENT 21 false false R22.htm 021 - Disclosure - NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://BIOS/role/NOTE5ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://BIOS/role/NOTE5ACCOUNTSPAYABLEANDACCRUEDEXPENSES 22 false false R23.htm 022 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) Sheet http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) Tables http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTS 23 false false R24.htm 023 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT (Tables) Sheet http://BIOS/role/NOTE10FAIRVALUEMEASUREMENTTables NOTE 10 - FAIR VALUE MEASUREMENT (Tables) Tables http://BIOS/role/NOTE10FAIRVALUEMEASUREMENT 24 false false R25.htm 024 - Disclosure - NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) Sheet http://BIOS/role/NOTE2GOINGCONCERNANDMANAGEMENTSLIQUIDITYPLANSDetails NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) Details http://BIOS/role/NOTE2GOINGCONCERNANDMANAGEMENTSLIQUIDITYPLANS 25 false false R26.htm 025 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://BIOS/role/NOTE3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://BIOS/role/NOTE3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 26 false false R27.htm 026 - Disclosure - NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Sheet http://BIOS/role/ScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareTable NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Details http://BIOS/role/NOTE3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 27 false false R28.htm 027 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT (Details) Sheet http://BIOS/role/NOTE4PROPERTYANDEQUIPMENTDetails NOTE 4 - PROPERTY AND EQUIPMENT (Details) Details http://BIOS/role/NOTE4PROPERTYANDEQUIPMENTTables 28 false false R29.htm 028 - Disclosure - NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment Sheet http://BIOS/role/ScheduleofPropertyPlantandEquipmentTable NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment Details http://BIOS/role/NOTE4PROPERTYANDEQUIPMENTTables 29 false false R30.htm 029 - Disclosure - NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities Sheet http://BIOS/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities Details http://BIOS/role/NOTE5ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables 30 false false R31.htm 030 - Disclosure - NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) Sheet http://BIOS/role/NOTE6SERIESC9CONVERTIBLEPREFERREDSTOCKDetails NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) Details http://BIOS/role/NOTE6SERIESC9CONVERTIBLEPREFERREDSTOCK 31 false false R32.htm 031 - Disclosure - NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) Sheet http://BIOS/role/NOTE7WARRANTANDDERIVATIVELIABILITIESDetails NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) Details http://BIOS/role/NOTE7WARRANTANDDERIVATIVELIABILITIES 32 false false R33.htm 032 - Disclosure - NOTE 8 - STOCKHOLDER EQUITY (Details) Sheet http://BIOS/role/NOTE8STOCKHOLDEREQUITYDetails NOTE 8 - STOCKHOLDER EQUITY (Details) Details http://BIOS/role/NOTE8STOCKHOLDEREQUITY 33 false false R34.htm 033 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) Sheet http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSDetails NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 34 false false R35.htm 034 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Sheet http://BIOS/role/ScheduleofSharebasedCompensationSharesAuthorizedunderStockOptionPlansbyExercisePriceRangeTable NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 35 false false R36.htm 035 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity Sheet http://BIOS/role/ScheduleofSharebasedCompensationStockOptionsActivityTable NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 36 false false R37.htm 036 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Sheet http://BIOS/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 37 false false R38.htm 037 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity Sheet http://BIOS/role/NonvestedRestrictedStockSharesActivityTable NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 38 false false R39.htm 038 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range Sheet http://BIOS/role/ScheduleofWarrantsorRightsSharesAuthorizedbyExercisePriceRangeTable NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 39 false false R40.htm 039 - Disclosure - NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights Sheet http://BIOS/role/ScheduleofStockholdersEquityNoteWarrantsorRightsTable NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights Details http://BIOS/role/NOTE9OPTIONSRESTRICTEDSTOCKUNITSANDWARRANTSTables 40 false false R41.htm 040 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT (Details) Sheet http://BIOS/role/NOTE10FAIRVALUEMEASUREMENTDetails NOTE 10 - FAIR VALUE MEASUREMENT (Details) Details http://BIOS/role/NOTE10FAIRVALUEMEASUREMENTTables 41 false false R42.htm 041 - Disclosure - NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Sheet http://BIOS/role/FairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationTable NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Details http://BIOS/role/NOTE10FAIRVALUEMEASUREMENTTables 42 false false R43.htm 042 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS (Details) Sheet http://BIOS/role/NOTE11SUBSEQUENTEVENTSDetails NOTE 11 - SUBSEQUENT EVENTS (Details) Details http://BIOS/role/NOTE11SUBSEQUENTEVENTS 43 false false All Reports Book All Reports bsgm-20160930.xml bsgm-20160930.xsd bsgm-20160930_cal.xml bsgm-20160930_def.xml bsgm-20160930_lab.xml bsgm-20160930_pre.xml true true ZIP 60 0001185185-16-005771-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001185185-16-005771-xbrl.zip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